ORIGINAL RESEARCH





Uses of dimedone for the synthesis of new heterocyclic derivatives with anti-tumor, c-Met, tyrosine, and Pim-1 kinases inhibitions

Rafat M. Mohareb¹ · Fatma O. Al Farouk¹ · Wagnat W. Wardakhan²

Received: 13 March 2018 / Accepted: 14 June 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

The reaction of dimedone (1) with any of the diazonium salts **2a–c** to give the arylhydrazone derivatives **3a–c**. The Gewald's reaction of any of compounds **3a–c** using elemental sulfur and either of malononitrile or ethyl cyanoacetate gave the thiophene derivatives **5a–f**, respectively. Compounds **5a**, **5c**, and **5e** underwent a series of heterocclization reactions to give potentially anticancer agents. The newly synthesized compounds were evaluated for their in vitro cytotoxic activity against c-Met kinase, and the six typical cancer cell lines (A549, H460, HT-29, MKN-45, U87MG, and SMMC-7721). All target compounds were initially tested for their anti-proliferative activity against human prostatic cancer PC-3 cell line. The most promising compounds were **5c**, **6c**, **6d**, **8e**, **8f**, **12d**, **14e**, and **14f** were further investigated against tyrosin kinase (c-Kit, Flt-3, VEGFR-2, EGFR, and PDGFR). Compounds **3c**, **5c**, **5d**, **6c**, **6d**, **8f**, **8g**, **8h**, **12c**, **12d**, **12f**, and **14f** were selected to examine their Pim-1 kinase inhibition activity where compounds **3c**, **6c**, **8g**, **12c**, and **14f** showed high activities.

Keywords Arylhydrazone · Anti-proliferative · Dimedone · Thiophene · Tryrosine kinase

Introduction

As typical reactive 1,3-dicarbonyl compounds, cyclohexane-1,3-dione, and its analogy 5,5-dimethyl cyclohexane-1,3dione(dimedone) have been widely used in versatile synthetic reactions (Dutra et al. 2014; Yadav et al. 2009). Dimedone is not only a typical reagent for Knoevenagel condensation, but also adds easily to electron-deficient alkenes via Michael addition. On the other hand, its one or two carbonyl groups could take part in substitution and cyclization reactions through the tautomerized enolate form. Thus the cascade reactions of addition, elimination and substitution could be achieved in many reactions involving dimedone. The reactions of cyclohexane-1,3-dione or dimedone with aldehydes have been extensively studied in the past years, from which several types of compounds have been produced according to the reaction conditions (Nadaraj et al. 2009). The normal

Rafat M. Mohareb raafat_mohareb@yahoo.com

² National Organization for Durg Control and Research, P. O. 29, Cairo, Egypt

Knoevenagel condensation of cyclohexane-1,3-done or dimedone with aldehydes have been conducted with numerous methods including promotion via amines (Chassainga et al. 2012), Lewis acids (Amoozadeh et al. 2015), surfactants (Deb Bhuyan 2005), zeolites (Jiao et al. 2011), ionic liquids (Khurana and Magoo 2009). The use of environmentally benign methods like in aqueous medium or in the absence of solvents (Nikoofar and Yielzoleh 2017) and the usage of ultrasound or microwave heating (Neimi and Nazif, 2014) have also been developed in recent years. The reactions usually proceed further through Michael addition reaction of the second molecule of dimedone to yield tetraketones as main products (Silva et al. 2018). On the other hand, tetraketones could be easily converted to 9-substituted 1,8-dioxo-xanthenes by dehydration step (Jiao et al. 2011). 1,8-Dioxo-xanthenes can also be directly prepared from the condensation of two molecules of dimedone with aromatic aldehydes in the presence of different kinds of catalysts (Ilangovan et al. 2011; Jiao et al. 2011) such as Amberlyst (Maripi et al. 2017), triethylbenzylammonium chloride (Darvish et al. 2007), diammonium hydrogen phosphate (Jin et al. 2006), sulfonic acid and ionic liquid under ultrasonic irradiation (Venkatesan et al. 2008; Rostamizadeh et al. 2010). In our continued interest in the design of new multicomponent reactions and the application in the synthesis of heterocyclic compounds (Mohareb et al. 2017, 2018), we found some unprecedented reaction

¹ Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

Scheme 1 Synthesis of compounds **3a–c**, **5a–f**, and **6a–f**



patterns in the reaction of the ary hydrazodimedone derivatives with elemental sulfur and cyanomethylene reagents to produce thiophene derivatives these were capable for further heterocyclization reactions to produce potential antitumor agents.

Results and discussion

The synthetic route to prepare a new class of biologically active heterocycles compounds linked dimedone moiety starting with the 2-arylhydrazodimedone derivatives. The synthetic pathways employed to prepare the new targeted derivatives are depicted in Schemes 1–3. Thus, the reaction of dimedone (1) with the aryldiazonium salts 2a-c in ethanol containing sodium acetate gave the arylhydrazone derivatives 3a-c, respectively. Compounds 3a-c exist in the arylhydrazone form as this structure is stabilized via the intramolecular N-H–O=C- hydrogen bonding (Drew 1982). We speculated that thiophene-fused derivatives can be obtained via the use of the Gewald's thiophene synthesis. Initially, we have investigated the reaction of any of the arylhydrazo compounds 3a-c with elemental sulfur and either of malonitrile (4a) or ethyl cyanoacetate (4b) to give the thiophene derivatives 5a-f, respectively. The structures of compounds 5a-f were based on their respective analytical

Scheme 2 Synthesis of compounds 8a-m and 10a-f



10a, X = H, $Y = NH_2$ **b**, X = H, Y = OH **c**, X = Cl, $Y = NH_2$ **d**, X = Cl, Y = OH **e**, $X = OCH_3$, $Y = NH_2$ **f**, $X = OCH_3$, Y - OH

and spectral data. Thus, the ¹H-NMR of **5a** showed, beside the expected signals, the presence of a singlet at δ 4.49 ppm (D₂O exchangeable) indicating the presence of the NH₂ group and a singlet at δ 2.70 ppm equivalent to the CH₂ group. In addition, the ¹³C-NMR specrum revealed the presence of signals at 142.8, 140.4, 138.7, 136.5, 131.8, 126.4, 124.3, and 120.2 corresponding to the C₆H₅ and tiophene carbons and a signal at 116.7 confirming the presence of the CN group. It is important to note that in such series of dimedone derivatives, although the 5,5-dimethyl groups as in the case of compounds 3a-c and the 7,7dimethyl moieties in compounds 5a-f showed a slight difference through the 1H-NMR like δ 1.08 and 1.09 ppm as in case of **3a**, however, the 13 C-NMR both of the two CH₃ groups gave one signal at 24.8. Such findings was in agreement with some reported literature (Drew 1982) although in other reports the ¹H-NMR and ¹³C-NMR showed two signals in each measurement (Gurumurthi et al. 2009).

We then turn our attention to the preparation of cinnoline derivatives through the reaction of any of compounds **5a,c,e** with either of malononitrile (**4a**) or ethyl cyanoacetate (**4b**) to give the 2,3,5,6-tetrahydrothieno[2,3-*h*]cinnoline derivatives **6a–f**, respectively (Scheme 1).

The reaction of any of compounds **6a–f** with either of hydrazine hydrate (**7a**) or phenylhydrazine (**7b**) gave the diarlhydrazone derivatives **8a–m**, respectively. The analytical and spectral data of the latter compounds were consistent with their respective products. Thus, the ¹H-NMR of compound **8a** (as an example) revealed the presence the two singlets at δ 4.47 and 5.03 ppm (D₂O exchangeable) corresponding to the two NH₂ groups beside the ¹³C-NMR spectrum that showed the presence of two signals 179.8 and 176.5 corresponding to the two C=N groups and signals at 179.8, 176.5 (C-4, C-5), 141.6, 140.8, 139.3, 135.9, 134.3, 128.6, 124.1, and 120.1 indicating the presence of C₆H₅ and thiophene carbons.





Encouraged by the initial success, we applied the optimal condition to the synthesis of a series of thienopyrimidino derivatives. Interestingly, the reaction of any of compounds **5a–f** with phenylisothiocyanate (**9**) gave the hexahydrobenzo[4,5]thieno[2,3-*d*]pyrimidin-4-yl)yttrium derivatives **10a–f**, respectively (Scheme 2). It is of an interest to mention that compounds **5a–f** and **10a–f** exist in the arylhydrazone form like compounds **3a–c** due to the stability of these tautomeric structures due to the intramolecular H-bonding (Drew 1982).

On the other hand, the reaction of any of compounds **10a–f** with hydroxylamine hydrochloride afforded the triazolo[4",5":5',6']benzo[1',2':4,5]thieno[2,3-*d*]pyrimidin-10yl)yttrium **12a–f**. Formation of the latter products were explained through the first reaction of the hydroxylamine to give the corresponding oxime derivative followed by dehydration. Finally, the reaction of any of compounds **5a–f** with the cinnamonitrile derivatives **13a** and **13b** gave the thieno[2,3-*g*]chromene derivatives **14a–m**, respectively. Compounds **14a–m** were structurally characterized by various spectroscopic techniques including ¹H, ¹³C-NMR, EI-MS, and IR.

Biology

Materials

Adenosine triphosphate (ATP), DMSO, MgCl₂ were obtained from Sigma (St. Louis, MO, USA) kinase buffer

 $\label{eq:table_$

Compound no	X	Y	R	IC ₅₀ (nM) c-Met	IC ₅₀ (nM) PC-3
3a	Н	_	_	8.25 ± 2.69	10.52 ± 2.84
3b	Cl	_	_	1.02 ± 0.63	2.48 ± 1.20
3c	OCH ₃	_	-	2.14 ± 0.92	3.84 ± 1.27
5a	Н	_	CN	12.28 ± 3.91	3.29 ± 1.59
5b	Н	_	COOEt	10.62 ± 2.59	4.26 ± 2.83
5c	Cl	_	CN	0.38 ± 0.19	0.22 ± 0.13
5d	Cl	_	COOEt	1.53 ± 0.87	2.62 ± 1.28
5e	OCH ₃	_	CN	12.49 ± 3.53	5.73 ± 1.69
5f	OCH_3	-	COOEt	14.02 ± 4.72	1.02 ± 0.82
6a	Н	NH	-	18.52 ± 6.93	10.72 ± 2.83
6b	Н	0	-	8.16 ± 2.62	10.93 ± 3.29
6c	Cl	NH	-	0.39 ± 0.21	0.63 ± 0.25
6d	Cl	0	-	0.08 ± 0.03	0.19 ± 0.66
6e	OCH_3	NH	-	12.59 ± 2.73	10.91 ± 3.62
6f	OCH_3	0	-	8.28 ± 2.59	7.39 ± 1.42
8a	Н	Н	CN	12.46 ± 4.63	6.28 ± 2.25
8b	Н	Ph	CN	8.28 ± 2.53	9.16 ± 2.72
8c	Н	Н	COOEt	8.62 ± 2.59	2.03 ± 0.83
8d	Н	Ph	COOEt	12.52 ± 4.90	18.39 ± 4.68
8e	Cl	Н	CN	0.25 ± 0.06	0.63 ± 0.09
8f	Cl	Ph	CN	0.08 ± 0.006	4.15 ± 1.80
8g	Cl	Н	COOEt	20.69 ± 4.80	10.63 ± 2.80
8h	Cl	Ph	COOEt	1.14 ± 0.79	2.38 ± 0.70
8i	OCH_3	Н	CN	6.37 ± 1.72	0.74 ± 0.23
8k	OCH_3	Ph	CN	8.39 ± 2.63	1.60 ± 0.69
81	OCH_3	Н	COOEt	14.27 ± 4.72	18.08 ± 5.27
8m	OCH_3	Ph	COOEt	8.06 ± 2.72	6.73 ± 1.52
10a	Н	NH_2	-	7.46 ± 2.79	1.81 ± 0.94
10b	Н	OH	-	10.28 ± 2.63	8.72 ± 3.92
10c	Cl	NH_2	-	4.73 ± 2.18	8.42 ± 2.93
10d	Cl	OH	-	1.05 ± 0.83	0.62 ± 0.25
10e	OCH ₃	NH_2	-	12.52 ± 2.69	5.79 ± 1.80
10f	OCH ₃	OH	-	3.72 ± 1.58	1.15 ± 0.82
12a	Н	NH_2	-	10.53 ± 2.80	17.19 ± 4.93
12b	Н	OH	-	8.69 ± 2.32	9.53 ± 3.86
12c	Cl	NH_2	-	2.39 ± 1.60	3.93 ± 1.72
12d	Cl	OH	-	0.83 ± 0.26	0.87 ± 0.15
12e	OCH ₃	NH_2	-	14.73 ± 4.74	8.82 ± 0.62
12f	OCH ₃	OH	-	15.26 ± 4.93	12.39 ± 3.49
14a	Н	NH_2	CN	6.18 ± 1.59	10.53 ± 2.90
14b	Н	OH	CN	8.63 ± 3.53	8.60 ± 3.32
14c	Н	NH ₂	COOEt	14.93 ± 4.72	18.25 ± 2.39
14d	Н	OH	COOEt	10.17 ± 3.80	8.63 ± 2.70
14e	Cl	NH ₂	CN	0.06 ± 0.05	0.54 ± 0.32
14f	Cl	OH	CN	0.07 ± 0.006	8.02 ± 2.52

Table 1 (c	ontinued)
------------	-----------

	,				
Compound no	X	Y	R	IC ₅₀ (nM) c-Met	IC ₅₀ (nM) PC-3
14g	Cl	NH_2	COOEt	2.28 ± 1.63	1.14 ± 0.83
14h	Cl	OH	COOEt	3.79 ± 1.64	0.64 ± 0.04
14i	OCH_3	NH_{2}	CN	6.73 ± 2.52	2.29 ± 1.59
14k	OCH_3	OH	CN	5.62 ± 2.49	1.07 ± 0.72
141	OCH ₃	NH_{2}	COOEt	14.63 ± 4.52	16.39 ± 3.63
14m	OCH_3	OH	COOEt	4.82 ± 1.29	6.73 ± 2.80
	_	-		Foretinib 1.16 ± 0.17	SGI-1776 4.86 ± 0.16

was prepared with 5 mmol L^{-1} MgCl₂, 1 mmol L^{-1} DTT, or 5 mmol L^{-1} MgCl₂, 1 mmol L^{-1} MnCl₂ and 1 mmol L^{-1} DTT. Receptor tyrosine kinases c-Kit, Flt-3, VEGFR-2, EGFR, and PDGFR were purchased from Carna Biosciences (Kobe, Japan).

HTRF kinase assay

The c-Met kinase activity of all compounds was evaluated (Table 1) using homogeneous time-resolved fluorescence (HTRF) assay as previously reported (Tang et al. 2016; Liu et al. 2016). In addition the most active compounds 5c, 6c, 6d, 8e, 8f, 12d, 14e, and 14f were further evaluated against other five tyrosine kinase (c-Kit, Flt-3, VEGFR-2, EGFR, and PDGFR) using the same screening method (Table 3). Briefly, 20 µg/mL poly (Glu, Tyr) 4:1 (Sigma) was precoated as a substrate in 384-well plates. Then 50 µL of 10 mM ATP (Invitrogen) solution diluted in kinase reaction buffer (50 µM HEPES, Ph 7.0, 1 M DTT, 1 M MgCl₂, 1 M MnCl₂, and 0.1% NaN₃) was added to each well. Various concentrations of compounds diluted in 10 µL of 1% DMSO (v/v) were used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted in 39 µL of kinase reaction buffer solution. The incubation time for the reactions was 30 min at 25 °C and stopped by the addition of 5 µL of Streptavidin-XL665 and 5 µL Tk Antibody Cryptate working solution to all of wells. The plates were read using Envision (PerkinElmer) at 320 and 615 nM. The inhibition rate (%) was calculated using the following equation: Percentage inhibition = 100 - 100[(Activity of enzyme with tested compounds – Min)/(Max -Min] × 100 (Max: the observed enzyme activity measured in the presence of enzyme, substrates, and cofactors; Min: the observed enzyme activity in the presence of substrates, cofactors and in the absence of enzyme). IC₅₀ values were calculated from the inhibition curves.

It has been reported that the c-Met kinase activity correlated to the prostate cancer where the transformation of prostate cancer from the primary androgen-sensitive to the androgen-insensitive status along with the gain of radioresistance that signaling by the receptor tyrosine kinase (RTK) c-Met played a key role in it. Firstly, an inverse correlation between the expression of androgen receptor (AR) and c-Met has been observed in prostate epithelium and prostate cancer cells (Knudsen et al. 2002; Humphrey et al. 1995). Secondly, AR signaling suppressed c-Met transcription, while the removal of androgen increased c-Met expression (Verras et al. 2007). Thirdly, it is observed that c-Met expression is high in late stage and bone metastatic prostate cancer (Knudsen et al. 2002). Furthermore, a recent study has demonstrated that c-Met expression has a close relationship with the cellular radiosensitivity (Bacco et al. 2011). Based on these reported observations, we studied the activity of the synthesized compounds toward PC-3 prostate cancer cell line, results were demonstrated through Table 1.

In vitro enzymatic assays

All the newly synthesized the aryl hydrazone derivatives were evaluated for their inhibitory activity toward c-Met enzyme (Zhang et al. 2012) using a homogeneous time-resolved fluorescence (HTRF) assay. Taking foretinib as the positive control, the results expressed as IC₅₀ were summarized in Table 1. The IC_{50} values are the average of at least three independent experiments.. The anti-proliferative activity of all target compounds against the human prostatic cancer PC-3 cell line were measured using MTT assay (Tiedt et al. 2011; Takayuki et al. 2010) using SGI-1776 as the reference drug. The mean values of three independent experiments, expressed as IC₅₀ values, were presented in Table 1. Most of the synthesized compounds exhibited potent anti-proliferative activity with IC_{50} values less than 30 μ M. Generally, the variations of substituents within the thienopyridine moiety together with the hetero cycle ring being attached have a notable influence on the anti-proliferative activity. The most potent compounds were the seven compounds 5c, 6c, 8e, 8f, 12d, 14e, and 14f.

As illustrated in Table 1, all the tested compounds displayed potent c-Met enzymatic activity with IC₅₀ values ranging from 0.08 to 25.28 nM and potent prostate PC-3 cell line with IC₅₀ values ranging from 0.06 to 20.69 nM. Compared with foretinib (IC₅₀ = 1.16 nM), seven compounds (**5c**, **6c**, **8e**, **8f**, **12d**, **14e**, and **14f**) exhibited equivalent or higher potency with IC₅₀ values less than 1.00 nM. It is clear from Table 1 that for compounds **3a–c**, compound **3b** (X = CI) showed IC₅₀ 1.02 nM against c-Met enzyme while it showed moderate potency toward PC-3 cell line. The reaction of any of compounds **3a–c** with elemental sulfur and either of malononitrile and ethyl cyanoacetate to give the thiophene derivatives **5a–f**, respectively. It is clear that compound **5c** (X = CI, R = CN) showed the highes potency among the six compounds against c-Met and PC-3 cell line with IC_{50} 's 0.38 and 0.22 nM, respectively. It was surprised that compound compound 5f ($X = OCH_3$, R =COOEt) showed low potency against c-Met enzyme but high potency against PC-3 cell line. Compounds 5c and 5f showed higher potency than foretinib against the c-Met enzyme. Considering the 2,3,5,6-tetrahydrothieno[2,3-h] cinnoline-4-carbonitrile derivatives 6a-f, it clear tha compounds 6c and 6d showed the highest potency against the c-Met enzyme and PC-cell line. Considering the bishydrazone derivatives 8a-m which were produced from the reaction of any of 5a-f with either of hydrazine hydrate or phenyhydrazine, it is clear that compounds 8a, 8b, 8c, 8d, 8g, 8l, and 8m revealed low potencies toward c-Met enzyme and PC-3 cell line. While compounds 8e, 8f, and 8h showed the highest potency analist c-Met enzyme. Compounds 8e, 8i, and 8k showed high inhibition toward PC-3 cell line. On the other hand for compounds tetrahydrobenzo[4,5]thieno[2,3*d*]pyrimidinone derivatives **10a–f**, it is clear that compound **10d** (X = Cl, Y = OH) showed the highest potency against c-Met enzyme with IC_{50} 1.05 nM while compounds 10a, 10d, and 10f showed the highest potencies against PC-3 cell lines with IC'₅₀ 1.81. 0.62 and 1.15 nM, respectively. Considering the nitrogen rich the triazolo[4",5":5',6']benzo [1',2':4,5]thieno[2,3-d]pyrimidine derivatives **12a-f**, it is obvious that compounds 12c and 12d were the most potent compounds through such series of compounds against the c-Met while compound 12d was the only compound that showed high cytotoxic compound toward the PC-3 cell line. Finally for the thieno[2,3-g]chromene derivatives 14a-m compounds 14e and 14f showed the highest potencies among the new synthesized compounds toward c-Met enzymatic activity. The potencies of compounds 14e and 14f were higher than that of the reference drug foretinib with IC₅₀'s 0.06 and 0.07 nM. On the other hand, compounds 4e, 14g, 14h, 14i, and 14k were the most potent compounds toward PC-cell line, in addition, thie potency higher than the reference drug SGI-1776 with IC₅₀'s 0.54, 1.14, 0.64, 2.29, and 1.07 nM, respectively.

Inhibition of tyrosine kinases (Enzyme IC50 (nM)

Compounds 5c, 6c, 6d, 8e, 8f, 12d, 14e, and 14f were selected for inhibition of the five tyrosine kinases c-Kit, Flt-3, VEGFR-2, EGFR, and PDGFR. It clear from Table 2 that compounds 5c (X = Cl, R = CN) and 14f (X = Cl, Y = OH, R = CN) were the most potent compounds among the tested compounds toward the five tyrosin kinases. Compound 8e showed high potency toward the three kinases c-Kit, VEGFR-2, and PDGFR with IC₅₀'s 0.29, 0.19, and 0.93 nM, respectively. In addition compound 6c showed activity against VEGFR-2 with IC₅₀ 0.96 nM. Compound 8f showed the lowest potencies among the tested compounds but compounds 6c and 12d showed moderate potencies.

Table 2 Inhibition of tyrosine kinases (Enzyme $\rm IC_{50}$ (nM) by compounds 5c, 6c, 6d, 8e, 8f, 12d, 14e, and 14f

Compound	c-Kit	Flt-3	VEGFR-2	EGFR	PDGFR
5c	0.08	0.25	0.62	0.27	0.39
6c	1.26	1.22	0.96	4.80	1.31
6d	0.69	0.77	0.38	0.52	0.93
8e	0.29	1.68	0.19	1.83	0.93
8f	6.73	4.82	6.29	8.31	4.90
12d	1.08	0.83	1.52	1.60	2.84
14e	0.49	0.28	0.19	0.83	0.35
14f	0.06	0.51	0.28	0.42	0.80
Foretinib	0.19	0.17	0.20	0.13	0.26

Cell proliferation assay

The anti-proliferative activities of the newly synthesized compounds (Table 3) were evaluated against the five c-Metdependent cancer cell lines (A549, HT-29, MKN-45, U87MG, and SMMC-7721) and one c-Met-independent cancer cell line (H460) using the standard MTT assay in vitro, with foretinib as the positive control (Li et al. 2013; Fathi et al. 2012). The cancer cell lines were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). Approximately 4×10^3 cells, suspended in MEM medium, were plated onto each well of a 96-well plate and incubated in 5% CO₂ at 37 °C for 24 h. The compounds tested at the indicated final concentrations were added to the culture medium and the cell cultures were continued for 72 h. Fresh MTT was added to each well at a terminal concentration of 5 µg/mL, and incubated with cells at 37 °C for 4 h. The formazan crystals were dissolved in 100 µL of DMSO each well, and the absorbency at 492 nM (for absorbance of MTT formazan) and 630 nM (for the reference wavelength) was measured with an ELISA reader. All of the compounds were tested three times in each cell line. The results expressed as IC₅₀ (inhibitory concentration 50%) were the averages of three determinations and calculated by using the Bacus Laboratories Incorporated Slide Scanner (Bliss) software.

In vitro cell assays

All the synthesized compounds were assessed the inhibitory activities against A549 (non-small cell lung cancer), H460 (human lung cancer), HT-29 (human colon cancer), and MKN-45 (human gastric cancer cancer) cancer cell lines together with foretinib as the positive control by a MTT assay. Furthermore, all compounds were further evaluated against U87MG (human glioblastoma) and SMMC-7721 (human liver cancer) cell lines. The results expressed as IC_{50} were summarized in Table 3. The IC_{50} values are the average of at

least three independent experiments. The data listed in Table 3 revealed that the compounds possessed moderate to strong cytotoxicity against the five tested cell lines in the single-digit IM range, and high selectivity for inhibition A549, H460, and MKN-45 cells. The promising compounds were 3b, 5d, 6c, 8f, 8e, 8f, 8g, 8h, 10c, 10d, 12c, 14f, and 14g were more active than foretinib against U87MG cell line with IC50 values of 0.59, 0.29, 0.38, 0.79, 0.35, 0.84, 0.80, 0.37, 0.25, 0.78, and 0.78 µM, respectively. The study of structure-activity relationships (SARs) indicated that these analogs showed similar SARs as summarized in the c-Met kinase level. Where compound **3b** showed high potency against the tesed cell line which was attributed to the presence of the 4-chkorophenyl moiety. On the other hand, compound 5d was the most potent compounds among the series **5a-f** due to the presence of the Cl and COOEt groups. For compounds 6a-f, it was obvious from Table 3 that compounds 6c and 6d were the most potent compounds. Considering compounds 10a-m, it was clear that compounds 8e, 8f, 8g, 8h, and 8m were the most cytotoxic compounds. Compounds 10c, 10f were the most active compounds among the series of 10a-f. The same for compounds 12a-f where comounds 12c and 12d were the most active compounds. It is obvious that the presence of the electronegative Cl group and the OH or NH₂ groups were responsible for the high potency of these compounds. Considering the thieno [2,3-g] chromene derivatives 14a-m it is clear from Table 3 that compounds 14e, 14f, and 14g were the most cytotoxic compounds among the twelve compounds. The highcytotoxicity of the three compounds 14e, 14f and 14g was attributed to the presence of the Cl and/or NH₂ or the OH groups.

Inhibition of selected toward Pim-1 kinase

Furthermore, compounds **3c**, **5c**, **5d**, **6c**, **6d**, **8f**, **8g**, **8h**, **12c**, **12d**, **12f**, and **14f** were selected to examine their Pim-1 kinase inhibition activity (Table 4) as these compounds showed high inhibition toward the c-Met kinase and the tested cancer cell lines at a range of 10 concentrations and the IC₅₀ values were calculated. Compounds **3c**, **6c**, **8g**, **12c**, and **14f** were the most potent to inhibit Pim-1 activity with IC₅₀ value of 0.18, 0.16, 0.36. 0.14, 0.17 μ M, while **5**, **6d**, **8f**, **8h**, **12d**, **12f**, and **13b** were less effective (IC₅₀ > 10 μ M). SGI-1776 was used as positive control with IC₅₀ 0.048 μ M in the assay. These profiles in combination with cell growth inhibition data of compounds **3c**, **5c**, **5d**, **6c**, **6d**, **8f**, **8g**, **8h**, **12c**, **12d**, **12f**, and **14f** were listed in Table 4 which indicated that Pim-1 was a potential target of these compounds.

Experimental

The solvents used through this work were dried prior to their use. All melting points of the synthesized compounds

Table 3 In vitro growth inhibitory effects $IC_{50} \pm SEM$ (μM) of the newly synthesized compounds against cancer cell lines

Compound no	$IC_{50} \pm SEM \ (\mu M)$						
	A549	H460	HT29	MKN-45	U87MG	SMMC-7721	
3a	8.38 ± 0.80	9.32 ± 2.08	9.26 ± 2.39	6.16 ± 1.42	8.59 ± 2.59	9.52 ± 3.51	
3b	0.26 ± 0.73	0.63 ± 0.25	1.08 ± 0.53	0.42 ± 0.23	0.59 ± 0.25	0.38 ± 0.16	
3c	1.47 ± 0.83	0.69 ± 0.32	0.84 ± 0.59	1.65 ± 0.39	0.84 ± 0.42	0.77 ± 0.25	
5a	8.55 ± 2.37	9.29 ± 2.63	8.37 ± 3.72	8.69 ± 2.48	9.30 ± 3.27	8.57 ± 2.63	
5b	8.32 ± 2.57	8.72 ± 2.68	9.29 ± 2.72	8.83 ± 2.60	9.38 ± 3.80	6.60 ± 1.73	
5c	9.28 ± 2.49	8.36 ± 2.59	10.17 ± 3.63	8.39 ± 2.68	9.49 ± 2.29	6.36 ± 2.67	
5d	0.26 ± 0.19	0.42 ± 0.22	0.19 ± 0.03	0.82 ± 0.39	0.29 ± 0.17	0.69 ± 0.29	
5e	1.20 ± 0.82	1.94 ± 0.82	2.73 ± 0.95	1.62 ± 0.89	1.59 ± 0.93	2.68 ± 0.83	
5f	9.53 ± 2.63	8.81 ± 2.92	9.68 ± 2.48	8.63 ± 3.77	8.53 ± 3.56	8.73 ± 2.52	
6a	8.57 ± 2.40	8.59 ± 2.41	7.62 ± 1.39	8.72 ± 3.80	9.59 ± 2.53	8.49 ± 2.17	
6b	8.59 ± 2.27	7.59 ± 1.63	8.74 ± 2.64	6.52 ± 2.63	8.93 ± 2.73	8.59 ± 1.62	
6с	0.34 ± 0.29	0.67 ± 0.53	0.72 ± 0.35	0.39 ± 0.17	0.38 ± 0.24	0.29 ± 0.16	
6d	0.42 ± 0.37	0.25 ± 0.16	0.84 ± 0.53	0.42 ± 0.28	1.29 ± 0.39	0.25 ± 0.09	
6e	6.26 ± 1.39	8.49 ± 2.23	8.58 ± 2.49	7.39 ± 2.38	8.59 ± 2.49	6.27 ± 1.25	
6f	8.42 ± 3.58	7.26 ± 2.59	9.27 ± 2.57	5.16 ± 1.42	6.69 ± 2.54	7.58 ± 2.62	
8a	9.53 ± 3.57	9.72 ± 3.89	8.42 ± 2.63	8.38 ± 1.83	8.90 ± 2.85	8.52 ± 3.41	
8b	8.59 ± 2.52	8.42 ± 2.49	6.73 ± 1.69	6.73 ± 1.73	6.74 ± 1.52	7.63 ± 2.51	
8c	5.42 ± 2.58	5.94 ± 2.39	6.25 ± 2.59	6.39 ± 2.16	5.62 ± 2.37	6.25 ± 1.94	
8d	6.42 ± 2.57	2.58 ± 1.82	3.39 ± 1.51	4.27 ± 1.72	6.29 ± 1.85	3.63 ± 1.59	
8e	1.27 ± 0.53	0.82 ± 0.57	0.83 ± 0.82	1.72 ± 0.94	0.79 ± 0.26	0.59 ± 0.24	
8f	0.26 ± 0.15	0.36 ± 0.14	0.39 ± 0.15	0.15 ± 0.06	0.35 ± 0.15	0.15 ± 0.08	
8g	0.67 ± 0.36	0.47 ± 0.25	1.69 ± 0.26	0.92 ± 0.36	0.84 ± 0.29	1.25 ± 0.48	
8h	0.25 ± 0.08	0.15 ± 0.07	0.68 ± 0.15	0.49 ± 0.15	0.80 ± 0.32	0.59 ± 0.38	
8i	6.42 ± 1.38	7.28 ± 2.59	6.24 ± 2.80	6.25 ± 1.64	7.90 ± 2.35	6.83 ± 2.49	
8k	2.27 ± 0.95	2.50 ± 0.81	1.25 ± 0.69	3.62 ± 1.27	2.49 ± 0.57	2.38 ± 0.32	
81	4.61 ± 1.65	3.72 ± 1.42	2.50 ± 0.82	2.63 ± 0.98	3.16 ± 1.80	2.57 ± 1.25	
8m	0.93 ± 0.32	1.59 ± 0.95	1.66 ± 0.94	1.37 ± 0.72	2.58 ± 0.96	2.25 ± 1.02	
10a	8.42 ± 2.57	9.28 ± 3.52	8.80 ± 3.63	6.70 ± 2.83	7.93 ± 1.27	6.38 ± 1.25	
10b	2.34 ± 0.95	3.59 ± 0.93	2.38 ± 0.84	4.53 ± 1.51	3.26 ± 1.42	4.28 ± 2.63	
10c	1.72 ± 0.69	1.38 ± 0.28	1.69 ± 0.36	0.69 ± 0.25	0.37 ± 0.15	2.81 ± 0.53	
10d	0.63 ± 0.42	0.82 ± 0.49	0.49 ± 0.83	0.08 ± 0.01	0.25 ± 0.03	0.92 ± 0.08	
10e	5.25 ± 0.53	7.31 ± 2.69	8.92 ± 2.73	6.27 ± 2.39	7.62 ± 2.49	6.80 ± 2.39	
10f	1.06 ± 0.78	1.52 ± 0.73	1.85 ± 0.59	0.93 ± 0.32	0.74 ± 0.29	1.28 ± 0.90	
12a	4.27 ± 1.58	3.94 ± 1.80	6.81 ± 2.39	5.62 ± 1.73	6.29 ± 2.32	4.56 ± 1.25	
12b	7.29 ± 1.42	8.92 ± 2.69	6.49 ± 2.73	8.28 ± 2.37	6.37 ± 1.62	7.79 ± 1.32	
12c	0.98 ± 0.63	1.08 ± 0.76	1.38 ± 0.69	0.89 ± 0.26	0.93 ± 0.69	1.03 ± 0.95	
12d	2.16 ± 1.35	1.28 ± 0.63	2.39 ± 0.83	1.92 ± 0.83	3.58 ± 1.62	2.72 ± 0.94	
12e	4.52 ± 1.39	3.70 ± 1.53	4.63 ± 2.59	3.22 ± 1.80	4.52 ± 1.63	5.72 ± 1.38	
12f	6.48 ± 2.53	6.70 ± 1.93	6.42 ± 1.59	4.84 ± 1.96	4.39 ± 1.73	5.84 ± 2.62	
14a	8.36 ± 2.58	6.29 ± 1.47	6.50 ± 1.62	6.49 ± 1.39	7.39 ± 2.92	3.69 ± 0.93	
14b	3.22 ± 1.79	7.39 ± 1.25	8.63 ± 2.44	6.39 ± 2.58	4.70 ± 2.09	9.48 ± 3.24	
14c	4.58 ± 1.37	3.53 ± 1.52	4.92 ± 1.62	5.63 ± 1.87	6.42 ± 2.74	6.29 ± 2.63	
14d	3.69 ± 1.52	4.62 ± 1.39	6.52 ± 2.59	8.32 ± 2.39	4.72 ± 1.49	3.83 ± 1.37	
14e	0.38 ± 0.15	0.83 ± 0.52	1.03 ± 0.95	0.54 ± 0.27	1.09 ± 0.82	0.98 ± 0.32	
14f	0.32 ± 0.31	0.94 ± 0.25	1.07 ± 0.88	0.63 ± 0.29	0.78 ± 0.36	1.18 ± 0.79	
14g	1.80 ± 0.73	0.89 ± 0.30	0.67 ± 0.42	0.93 ± 0.42	0.78 ± 0.39	0.73 ± 0.26	
0							

Table 3 (continued)

Compound no	$IC_{50} \pm SEM \ (\mu M)$							
	A549	H460	HT29	MKN-45	U87MG	SMMC-7721		
14h	3.38 ± 1.52	2.26 ± 0.53	1.36 ± 0.53	2.63 ± 0.88	1.29 ± 0.25	2.28 ± 0.69		
14i	10.17 ± 2.39	9.38 ± 2.42	10.49 ± 3.80	8.52 ± 2.95	8.53 ± 2.27	9.73 ± 2.59		
14k	8.25 ± 1.73	10.62 ± 3.60	8.72 ± 2.55	8.20 ± 1.83	6.39 ± 1.72	7.93 ± 1.27		
14l	9.87 ± 1.65	6.48 ± 1.33	7.202 ± 2.72	8.73 ± 2.68	6.49 ± 2.42	4.83 ± 1.59		
14m	6.39 ± 1.52	1.38 ± 0.69	3.34 ± 1.48	1.89 ± 0.88	2.84 ± 1.52	4.58 ± 1.38		
Foretinib	0.08 ± 0.01	0.18 ± 0.03	0.15 ± 0.023	0.03 ± 0.0055	0.90 ± 0.13	0.44 0.062		

Table 4 The inhibitor activity of compounds 3c, 5c, 5d, 6c, 6d, 8f, 8g, 8h, 12c, 12d, 12f and 14f on Pim-1 Kinase

Compound	Inhibition ratio At 10 μM	IC ₅₀ (µM)
3c	94	0.18
5c	32	>10
5d	96	0.16
6с	92	0.36
6d	21	>10
8f	18	>10
8g	98	0.14
8h	31	>10
12c	97	0.12
12d	28	>10
12f	26	>10
14f	95	0.17
SGI-1776	-	0.048

were recorded on Buchi melting point apparatus D-545; IR spectra (KBr discs) were recorded on Bruker Vector 22 instrument. ¹³C-NMR and ¹H-NMR spectra were recorded on Bruker DPX200 instrument in DMSO-d₆ with TMS as internal standard. Chemical shifts are mentioned in δ (ppm). Mass spectra were measured using EIMS (Shimadzu) and ESI-esquire 3000 Bruker Daltonics instrument. Elemental analyses were carried out using the Microanalytical Data center at Cairo University. The completion of all reactions was monitored by TLC on 2 × 5 cm pre-coated silica gel 60 F254 plates of thickness of 0.25 mm (Merck).

General procedure for the synthesis of the arylhydrazone derivatives 3a-c

To a solution of dimedone (1.40 g, 0.01 mol) in ethanol (40 mL) containing sodium acetate (4.0 g) any of benzenediazonium chloride (0.01 mol), 4-chlorobenzenediazonium chloride (0.01 mol) or 4-methoxybenzenediazonium chloride (0.01 mol) or 4-methoxybenzenediazonium chloride (0.01 mol) [prepared through the addition of sodium nitrite (0.70 g, 0.01 mol) to a cold solution $0-5 \text{ }^\circ\text{C}$ any of aniline (0.92 g, 0.01 mol), 4-chloroaniline (1.27 g, 0.01 mol) or 4methoxyaniline (1.23 g, 0.01 mol) dissolved in concentrated hydrochloric acid (9.0 mL, 18 mol) was added with continuous stirring] added. The reaction mixture was stirred at room temperature for 2 h and the formed solid product, in each case, was collected by filtration.

5,5-Dimethyl-2-(2-phenylhydrazono)cyclohexane-1,3-dione (3a)

Orange-red crystals (ethanol), yield 70% (1.71 g), m.p. 149–152 °C; (IR (KBr) ν max 3486–3325, 3055, 2984, 1689, 1687, 1635, 1580; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.28$ (s, 1H, D₂O exchangeable, NH), 7.26–7.39 (m, 5H, C₆H₅), 2.73, 2.71 (2s, 4H, 2CH₂), 1.08, 1.09 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 182.3$ (C-2, C-4), 133.5, 127.2, 124.8, 120.5 (C₆H₅), 50.3 (C-4, C-6), 24.8 (2CH₃); EIMS: *m/z* 244 [M]⁺ (48%); Analysis Calcd for C₁₄H₁₆N₂O₂ (244.29): C, 68.83; H, 6.60; N, 11.47%. Found: C, 68.69; H, 6.49; N, 11.72%.

2-(2-(4-Chlorophenyl)hydrazono)-5,5-dimethylcyclohexane-1,3-dione (3b)

Orange crystals (ethanol), yield 78% (2.16 g), m.p. 168–170 °C; (IR (KBr) ν max 3493–3335, 3050, 2985, 1689, 1688, 1632, and 1583; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.26$ (s, 1H, D₂O exchangeable, NH), 7.22–7.49 (m, 4H, C₆H₄), 2.71, 2.70 (2 s, 4H, 2CH₂), 1.05, 1.07 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 182.3$ (C-2, C-4), 135.8, 128.5, 126.7, 121.8 (C₆H₄), 50.1 (C-4, C-6), 24.5 (2CH₃); EIMS: *m*/*z* 278 [M]⁺ (38%); Analysis Calcd for C₁₄H₁₅ClN₂O₂ (278.73): C, 60.33; H, 5.42; N, 10.05%. Found: C, 60.42; H, 5.70; N, 9.85%.

2-(2-(4-Methoxyphenyl)hydrazono)-5,5dimethylcyclohexane-1,3-dione (3c)

Orange crystals (ethanol), yield 69% (1.89 g), m.p. 144–147 °C; (IR (KBr) ν max 3482–3317, 3050, 2987, 1688, 1686, 1630, 1584; ¹H-NMR (DMSO-d₆, 200 MHz): δ =

8.27 (s, 1H, D₂O exchangeable, NH), 7.20–7.46 (m, 4H, C₆H₄), 3.68 (s, 3 H, OCH₃), 2.74, 2.71 (2 s, 4H, 2CH₂), 1.06, 1.08 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 182.3 (C-2, C-4), 135.5, 127.8, 125.6, 120.3 (C₆H₄), 52.6 (OCH₃), 50.2 (C-4, C-6), 24.6 (2CH₃); EIMS: *m*/z 274 [M]⁺ (28%); Analysis Calcd for C₁₅H₁₈N₂O₃ (274.32): C, 65.68; H, 6.61; N, 10.21%. Found: C, 65.73; H, 6.49; N, 10.08%.

General procedure for the synthesis of the 6,7dihydrobenzo[b]thiophen-5(4H)-one derivatives 5a-f

To a solution of any of compound **3a** (2.44 g, 0.01 mol), 3b (2.78 g, 0.01 mol) or **3c** (2.74 g, 0.01 mol) in 1,4-dioxan (40 mL) containing triethylamine (0.50 g) each of elemental sulfur (0.32 g, 0.01 mol) and either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.3 g, 0.01 mol) were added. The reaction mixture was heated under reflux for 2 h then left to cool and the formed solid product, in each case was collected by filtration.

2-Amino-7,7-dimethyl-5-oxo-4-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo-[b]thiophene-3-carbonitrile (5a)

Yellow crystals (ethanol), yield 78% (2.52 g), m.p. 213–216 °C; (IR (KBr) ν max 3474–3316, 3056, 2982, 2220, 1688, 1635, 1565; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.26$ (s, 1H, D₂O exchangeable, NH), 7.28–7.38 (m, 5H, C₆H₅), 4.49 (s, 2H, D₂O exchangeable, NH₂), 2.70 (s, 2H, CH₂), 1.06, 1.05 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.2$ (C-5), 142.8, 140.4, 138.7, 136.5, 131.8, 126.4, 124.3, 120.2 (C₆H₅, C-2, C-3, C-3a, C-7a) 116.7 (CN), 50.3 (C-4, C-6), 24.6 (2CH₃), 38.6 (C-7); EIMS: m/z 324 [M]⁺ (32%); Analysis Calcd for C₁₇H₁₆N₄OS (324.40): C, 62.94; H, 4.97; N, 17.27; S, 9.88%. Found: C, 63.15; H, 5.21; N, 17.06; S, 10.02%.

Ethyl 2-amino-7,7-dimethyl-5-oxo-4-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5b)

Yellow crystals (ethanol), yield 68% (2.52 g), m.p. 177–179 °C; (IR (KBr) ν max 3481–3324, 3054, 2980, 1687, 1632, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.28 (s, 1H, D₂O exchangeable, NH), 7.26–7.39 (m, 5H, C₆H₅), 4.46 (s, 2H, D₂O exchangeable, NH₂), 4.22 (q, 2H, J = 7.11 Hz, CH₂), 2.72 (s, 2H, CH₂), 1.13 (t, 3H, J = 7.11 Hz, CH₃), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.4 (C-4), 164.6, 168.2 (C-5, ester C=O), 141.8, 138.9, 137..5, 136.8, 132.2, 128.1, 126.7, 120.9 (C₆H₅, C-2, C-3, C-3a, C-7a), 50.3 (C-4, C-6), 38.5 (C-7), 24.6 (2CH₃); EIMS: *m*/*z* 371 [M]⁺ (28%); Analysis Calcd for C₁₉H₂₁N₃O₃S (371.45): C, 61.44; H, 5.70; N, 11.31; S, 8.63%. Found: C, 61.58; H, 5.39; N, 11.42; S, 8.82%.

2-Amino-4-(2-(4-chlorophenyl)hydrazono)-7,7-dimethyl-5oxo-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carbonitrile (5c)

Yellow crystals (ethanol), yield 80% (2.86 g), m.p. 207–210 °C; (IR (KBr) ν max 3477–3321, 3056, 2980, 2220, 1689, 1630, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.25$ (s, 1H, D₂O exchangeable, NH), 7.47–7.22 (m, 4H, C₆H₄), 4.47 (s, 2H, D₂O exchangeable, NH₂), 2.75 (s, 2H, CH₂), 1.07, 1.02 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.4$ (C-4), 164.9 (C-5), 142.6, 141.8, 138.5, 136.9, 130.8, 125.6, 123.8, 120.3 (C₆H₅, C-2, C-3, C-3a, C-7a), 116.8 (CN), 50.2 (C-4, C-6), 38.5 (C-7), 24.6 (2CH₃); EIMS: *m*/z 358 [M]⁺ (41%); Analysis Calcd for C₁₇H₁₅ClN₄OS (358.85): C, 56.90; H, 4.21; N, 15.61; S, 8.94%. Found: C, 56.76; H, 4.39; N, 15.80; S, 8.76%.

Ethyl 2-amino-4-(2-(4-chlorophenyl)hydrazono)-7,7dimethyl-5-oxo-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3carboxylate (5d)

Yellow crystals (ethanol), yield 73% (2.95 g), m.p. 205–208 °C; (IR (KBr) ν max 3496–3317, 3056, 2983, 1689, 1630, 1552; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.25 (s, 1H, D₂O exchangeable, NH), 7.47–7.23 (m, 4H, C₆H₄), 4.49 (s, 2H, D₂O exchangeable, NH₂), 4.24 (q, 2H, J = 6.83 Hz, CH₂), 2.72 (s, 2H, CH₂), 1.13 (t, 3H, J = 6.83 Hz, CH₃), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.7 (C-4), 168.2, 164.7 (C-5, ester CO), 141.8, 140.6, 138.5, 137.3, 131.8, 127.9, 126.4, 120.4 (C₆H₅, C-2, C-3, C-3a, C-7a) 52.6 (O<u>CH₂CH₃</u>), 50.1 (C-4, C-6), 16.2 (OCH₂<u>CH₃</u>), 38.7 (C-7), 24.8 (2CH₃); EIMS: *m/z* 405 [M]⁺ (42%); Analysis Calcd for C₁₉H₂₀ClN₃O₃S (405.90): C, 56.22; H, 4.97; N, 10.35; S, 7.90%. Found: C, 56.39; H, 5.16; N, 10.63; S, 8.03%.

2-Amino-4-(2-(4-methoxyphenyl)hydrazono)-7,7-dimethyl-5-oxo-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carbonitrile (5e)

Yellow crystals (ethanol), yield 68% (2.40 g), m.p. 258–261 °C; (IR (KBr) ν max 3449–3349, 3054, 2983, 2222, 1687, 1632, 1564; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.26$ (s, 1H, D₂O exchangeable, NH), 7.45–7.27 (m, 4H, C₆H₄), 4.49 (s, 2H, D₂O exchangeable, NH₂), 3.69 (s, 3H, OCH₃), 2.79 (s, 2H, CH₂), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$ (C-4), 165.2 (C-5), 142.2, 141.8, 138.2, 134.5, 131.6, 128.3, 125.3, 120.8 (C₆H₄, C-2, C-3, C-3a, C-7a), 116.9 (CN), 52.6 (OCH₃), 50.4 (C-4, C-6), 38.8 (C-7), 24.8 (2CH₃),; EIMS: *m/z* 354 [M]⁺ (36%); Analysis Calcd for C₁₈H₁₈N₄O₂S (354.43): C, 61.00; H, 5.12; N, 15.81; S, 9.05%. Found: C, 60.85; H, 4.94; N, 15.69; S, 8.95%.

Ethyl 2-amino-4-(2-(4-methoxyphenyl)hydrazono)-7,7dimethyl-5-oxo-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3carboxylate (5f)

Yellow crystals (ethanol), yield 77% (3.08 g), m.p. 156–159 °C; (IR (KBr) ν max 3484–3326, 3056, 2982, 1688, 1630, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.27 (s, 1H, D₂O exchangeable, NH), 7.39–7.27 (m, 4H, C₆H₄), 4.46 (s, 2H, D₂O exchangeable, NH₂), 4.21 (q, 2H, J = 7.02 Hz, CH₂), 2.76 (s, 2H, CH₂), 1.12 (t, 3H, J = 7.02 Hz, CH₃), 1.05, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.5 (C-4), 165.2, 168.7 (C-5, ester CO),), 142.6, 140.3, 136.8, 134.7, 132.6, 127.5, 125.3, 120.5 (C₆H₄, C-2, C-3, C-3a, C-7a), 52.8 (OCH₃), 52.4 (OCH₂CH₃), 50.3 (C-4, C-6), 38.9 (C-7), 24.7 (2CH₃), 16.8 (OCH₂CH₃),; EIMS: *m/z* 401 [M]⁺ (32%); Analysis Calcd for C₂₀H₂₃N₃O₄S (401.48): C, 59.83; H, 5.77; N, 10.47; S, 7.99%. Found: C, 59.73; H, 5.80; N, 10.59; S, 8.15%.

General procedure for the synthesis of the 2,3,5,6tetrahydrothieno[2,3-*h*]cinnoline derivatives 6a-f

To a solution of any of compounds **5a** (3.24 g, 0.01 mol), **5c** (3.58 g, 0.01 mol), and **5e** (3.54 g, 0.01 mol) in 1,4-dioxan (40 mL) containing triethylamine (0.50 g, 0.01 mol) either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 3 h then poured onto ice/ water containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

8-Amino-3-imino-6,6-dimethyl-2-phenyl-2,3,5,6tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6a)

Yellow crystals (ethanol), yield 78% (2.90 g), m.p. 187–190 °C; (IR (KBr) ν max 3498–3326, 3054, 2983, 2224, 2220, 1632, 1564; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.28$ (s, 1H, D₂O exchangeable, NH), 7.38–7.25 (m, 5H, C₆H₅), 4.47 (s, 2H, D₂O exchangeable, NH₂), 2.79 (s, 2H, CH₂), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 178.5$, 175.4 (C-3, C-9b), 143.8, 142.6, 140.9, 138.3, 137.0, 136.5, 135.3, 127.5, 124.6, 120.5 (C₆H₅, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.9, 117.3 (2CN), 50.3 (C-4, C-6), 38.4 (C-6), 24.1 (2CH₃); EIMS: *m/z* 372 [M]⁺ (22%); Analysis Calcd for C₂₀H₁₆N₆S (372.45): C, 64.50; H, 4.33; N, 22.56; S, 8.61%. Found: C, 64.68; H, 4.51; N, 22.69; S, 8.79%.

8-Amino-3-oxo-6,6-dimethyl-2-phenyl-2,3,5,6tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6b)

Yellow crystals (ethanol), yield 83% (3.09 g), m.p. 233–236 °C; (IR (KBr) vmax 3474–3352, 3056, 2983,

2221, 2220, 1689, 1636, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 7.41-7.25$ (m, 5H, C₆H₅), 4.49 (s, 2H, D₂O exchangeable, NH₂), 2.73 (s, 2H, CH₂), 1.06, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 178.8$, 168.2 (C-3, C-9b), 143.6, 142.2, 140.5, 138.6, 137.2, 136.2, 133.8, 129.9, 126.2, 120.8 (C₆H₅, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.8, 117.2 (2CN), 50.1 (C-4, C-6), 38.7 (C-6), 24.5 (2CH₃); EIMS: *m/z* 373 [M]⁺ (42%); Analysis Calcd for C₂₀H₁₅N₅OS (373.43): C, 64.33; H, 4.05; N, 18.75; S, 8.59%. Found: C, 64.58; H, 4.19; N, 18.93; S, 8.64%.

8-Amino-2-(4-chlorophenyl)-3-imino-6,6-dimethyl-2,3,5,6-tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6c)

Yellow crystals (ethanol), yield 72% (2.92 g), m.p. 177–179 °C; (IR (KBr) ν max 3480–3317, 3054, 2982, 2222, 2220, 1646, 1556; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.41$ (s, 1H, D₂O exchangeable, NH), 7.48–7.21 (m, 4H, C₆H₄), 4.43 (s, 2H, D₂O exchangeable, NH₂), 2.77 (s, 2H, CH₂), 1.08, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$, 175.6 (C-3, C-9b), 143.3, 141.8, 140.2, 139.4, 138.1, 136.8, 134.5, 129.4, 127.8, 122.1 (C₆H₅, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.7, 117.2 (2CN), 50.3 (C-4, C-6), 38.6 (C-6), 24.3 (2CH₃); EIMS: *m/z* 406 [M]⁺ (38%); Analysis Calcd for C₂₀H₁₅ClN₆S (406.89): C, 59.04; H, 3.72; N, 20.65; S, 7.88%. Found: C, 59.25; H, 3.82; N, 20.73; S, 8.04%.

8-Amino-2-(4-chlorophenyl)-6,6-dimethyl-3-oxo-2,3,5,6-tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6d)

Yellow crystals (ethanol), yield 58% (2.36 g), m.p. 177–179 °C; (IR (KBr) ν max 3458–3315, 3055, 2980, 2222, 2220, 1688, 1633, 1562; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 7.46-7.23$ (m, 4H, C₆H₄), 4.42 (s, 2H, D₂O exchangeable, NH₂), 2.78 (s, 2H, CH₂), 1.08, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 178.5$, 167.9 (C-3, C-9b), 143.3, 142.7, 141.8, 139.2, 137.7, 136.1, 132.3, 127.3, 123.1, 120.5 (C₆H₄, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.5, 117.1 (2CN), 50.5 (C-4, C-6), 38.3 (C-6), 24.6 (2CH₃); EIMS: *m/z* 407 [M]⁺ (28%); Analysis Calcd for C₂₀H₁₄ClN₅OS (407.88): C, 58.89; H, 3.46; N, 17.17; S, 7.86%. Found: C, 58.66; H, 3.59; N, 16.93; S, 7.69%.

8-Amino-3-imino-2-(4-methoxyphenyl)-6,6-dimethyl-2,3,5,6-tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6e)

Yellow crystals (ethanol), yield 78% (3.15 g), m.p. 231–233 °C; (IR (KBr) ν max 3458–3341, 3056, 2982, 2223, 2220, 1642, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.45 (s, 1H, D₂O exchangeable, NH), 7.43–7.27 (m, 4H, C₆H₄), 4.41 (s, 2H, D₂O exchangeable, NH₂), 3.68 (s, 3H,

OCH₃), 2.79 (s, 2H, CH₂), 1.07, 1.05 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.9$, 175.3 (C-3, C-9b), 142.3, 141.5, 140.9, 138.2, 137.8, 135.3, 134.2, 128.1, 127.3, 122.8 (C₆H₅, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.9, 117.2 (2CN), 52.6 (OCH₃), 50.1 (C-4, C-6), 38.5 (C-6), 24.6 (2CH₃); EIMS: *m/z* 402 [M]⁺ (58%); Analysis Calcd for C₂₁H₁₈N₆OS (402.47): C, 62.67; H, 4.51; N, 20.88; S, 7.97%. Found: C, 62.80; H, 4.92; N, 20.63; S, 8.7%.

8-Amino-2-(4-methoxyphenyl)-6,6-dimethyl-3-oxo-2,3,5,6-tetrahydrothieno[2,3-*h*]cinnoline-4,9-dicarbonitrile (6f)

Yellow crystals (ethanol), yield 88% (3.54 g), m.p. 244–246 °C; (IR (KBr) ν max 3473–3328, 3054, 2983, 2220, 1688, 1642, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.45$ (s, 1H, D₂O exchangeable, NH), 7.46–7.23 (m, 4H, C₆H₄), 4.41 (s, 2H, D₂O exchangeable, NH₂), 3.69 (s, 3H, OCH₃), 2.79 (s, 2H, CH₂), 1.07, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.9$, 175.3 (C-3, C-9b), 142.8, 141.6, 140.8, 138.3, 136.4, 135.1, 132.8, 129.6, 126.3, 121.8 (C₆H₅, C-2, C-3, C-6a, C-9a, C-4, C-4a), 116.9, 117.4 (2CN), 50.1 (C-4, C-6), 38.3 (C-6), 24.6 (2CH₃); EIMS: *m/z* 403 [M]⁺ (46%); Analysis Calcd for C₂₁H₁₇N₅O₂S (403.46): C, 62.52; H, 4.25; N, 17.36; S, 7.95%. Found: C, 562.80; H, 4.73; N, 17.46; S, 8.26%.

General procedure for the synthesis of the tetrahydrobenzo [b]thiophene derivatives 8a-m

To a solution of any of **5a** (3.24 g, 0.01 mol), **5b** (3.71 g, 0.01 mol), **5c** (3.58 g, 0.01 mol), **5d** (4.05 g, 0.01 mol), **5e** (3.54 g, 0.01 mol) or **5f** (4.01 g, 0.01 mol) in ethanol (40 mL) either of hydrazinehydrate (0.50 mL, 0.01 mol) or phenylhydrazine (1.08 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 3 h then poured onto ice/water containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

2-Amino-5-hydrazono-7,7-dimethyl-4-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carbonitrile (8a)

Yellow crystals (ethanol), yield 74% (2.50 g), m.p. 196–198 °C; (IR (KBr) ν max 3496–3335, 3054, 2980, 2223, 1655, 1561; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.29, (s, 1H, D₂O exchangeable, NH), 7.39–7.29 (m, 5H, C₆H₅), 4.47, 5.03 (2s, 4H, D₂O exchangeable, 2NH₂), 2.73 (s, 2H, CH₂), 1.09, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.8, 176.5 (C-4, C-5), 141.6, 140.8, 139.3, 135.9, 134.3, 128.6, 124.1, 120.1 (C₆H₅, C-2, C-3, C-3a, C-7a) 116.9 (CN), 50.3 (C-4), 38.8 (C-7), 24.6 (2CH₃); EIMS: *m/z* 338 [M]⁺ (18%); Analysis Calcd for C₁₇H₁₈N₆S (338.43): C, 60.33; H, 5.36; N, 24.83; S, 9.47%. Found: C, 60.54; H, 5.48; N, 24.65; S, 9.61%.

2-Amino-7,7-dimethyl-4,5-bis(2-phenylhydrazono)-4,5,6,7tetrahydrobenzo[*b*]thiophene-3-carbonitrile (8b)

Orange crystals (ethanol), yield 69% (2.85 g), m.p. 155–158 °C; (IR (KBr) ν max 3479–3317, 3055, 2980, 2220, 1653, 1563; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.32$, 8.26 (2s, 2H, D₂O exchangeable, 2NH), 7.37–7.24 (m, 10H, 2C₆H₅), 4.49 (s, 2H, D₂O exchangeable, NH₂), 2.76 (s, 2H, CH₂), 1.07, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.7$, 176.3 (C-4, C-5), 142.8, 140.6, 137.8, 135.4, 134.6, 127.3, 126.5, 125.2, 124.8, 123.5, 122.7, 120.1 (2C₆H₅, C-2, C-3, C-3a, C-7a) 116.5 (CN), 50.2 (C-4), 38.3 (C-7), 24.2 (2CH₃); EIMS: *m*/*z* 414 [M]⁺ (65%); Analysis Calcd for C₂₃H₂₂N₆S (414.53): C, 66.64; H, 5.35; N, 20.27; S, 7.74%. Found: C, 66.86; H, 5.53; N, 20.38; S, 7.93%.

Ethyl 2-amino-5-hydrazono-7,7-dimethyl-4-(2phenylhydrazono)-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3carboxylate (8c)

Orange crystals (ethanol), yield 69% (2.85 g), m.p. 155–158 °C; (IR (KBr) ν max 3479–3332, 3053, 2980, 1689, 1653, 1563; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.27 (s, 1H, D₂O exchangeable, NH), 7.39–7.27 (m, 5H, C₆H₅), 4.47, 5.13 (2s, 4H, D₂O exchangeable, 2NH₂), 4.22 (q, 2H, J = 6.38 Hz, OCH₂CH₃), 2.73 (s, 2H, CH₂), 1.16 (t, 3H, J = 6.38 Hz, OCH₂CH₃), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.9, 176.5 (C-4, C-5), 164.8 (ester CO), 142.8, 140.6, 137.8, 134.6, 126.5, 124.8, 122.7, 120.1 (C₆H₅, C-2, C-3, C-3a, C-7a), 52.6 (OCH₂CH₃), 50.5 (C-4), 38.2 (C-7), 24.5 (2CH₃), 19.2 (OCH₂CH₃); EIMS: *m*/z 385 [M]⁺ (78%); Analysis Calcd for C₁₉H₂₃N₅O₂S (385.48): C, 59.20; H, 6.01; N, 18.17; S, 8.32%. Found: C, 59.30; H, 5.88; N, 18.27; S, 8.60%.

Ethyl 2-amino-7,7-dimethyl-4,5-bis(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxylate (8d)

Reddish brown crystals (ethanol), yield 73% (3.36 g), m.p. 207–210 °C; (IR (KBr) ν max 3459–3341, 3055, 2980, 1688, 1653, 1563; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.27 (s, 1H, D₂O exchangeable, NH), 7.41–7.29 (m, 10H, 2C₆H₅), 4.43, 5.11 (2s, 4H, D₂O exchangeable, 2NH₂), 4.22 (q, 2H, J = 7.11 Hz, OCH₂CH₃), 2.78 (s, 2H, CH₂), 1.13 (t, 3 H, J = 7.11 Hz, OCH₂CH₃), 1.06, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.5, 176.1 (C-4, C-5), 164.9 (ester CO), 142.9, 141.2, 138.6, 137.4, 134.6, 126.5, 125.8, 124.2, 123.1, 122.3, 121.2, 120.0 (2C₆H₅, C-2, C-3, C-3a, C-7a), 52.8 (OCH₂CH₃); EIMS: *m/z* 461 [M]⁺ (36%); Analysis Calcd for C₂₅H₂₇N₅O₂S (461.58): C, 65.05; H, 5.90; N, 15.17; S, 6.95%. Found: C, 64.87; H, 5.79; N, 15.35; S, 7.17%.

2-Amino-4-(2-(4-chlorophenyl)hydrazono)-5-hydrazono-7,7dimethyl-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3carbonitrile (8e)

Yellow crystals (ethanol), yield 83% (3.08 g), m.p. 211–214 °C; (IR (KBr) ν max 3477–3321, 3055, 2980, 2220, 1655, 1563; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.3$ (s, 1H, D₂O exchangeable, NH), 7.48–7.23 (m, 4H, C₆H₄), 4.45, 5.06 (2s, 4H, D₂O exchangeable, 2NH₂), 2.76 (s, 2H, CH₂), 1.07, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$, 176.3 (C-4, C-5), 143.3, 141.6, 137.1, 135.2, 134.0, 127.3, 122.8, 120.6 (C₆H₄, C-2, C-3, C-3a, C-7a) 116.6 (CN), 50.6 (C-4), 38.4 (C-7), 24.9 (2CH₃); EIMS: *m/z* 372 [M]⁺ (42%); Analysis Calcd for C₁₇H₁₇ClN₆S (372.88): C, 54.76; H, 4.60; N, 22.54; S, 8.60%. Found: C, 54.49; H, 4.82; N, 22.80; S, 8.74%.

2-amino-4-(2-(4-chlorophenyl)hydrazono)-7,7-dimethyl-5-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carbonitrile (8f)

Red crystals (ethanol), yield 72% (3.22 g), m.p. 148–151 ° C; (IR (KBr) ν max 3469–3326, 3056, 2982, 2220, 1657, 1561; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.36$, 8.29 (2s, 2H, D₂O exchangeable, 2NH), 7.47–7.21 (m, 9H, C₆H₅, C₆H₄), 4.49 (s, 2H, D₂O exchangeable, NH₂), 2.76 (s, 2H, CH₂), 1.07, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.5$, 176.1 (C-4, C-5), 142.5, 140.3, 136.9, 135.1, 134.8, 126.7, 126.2, 125.0, 124.9, 123.8, 122.3,120.8 (C₆H₅, C₆H₄, C-2, C-3, C-3a, C-7a) 116.9 (CN), 50.5 (C-4), 38.6 (C-7), 24.3 (2CH₃); EIMS: *m/z* 448 [M]⁺ (26%); Analysis Calcd for C₂₃H₂₁ClN₆S (448.97): C, 61.53; H, 4.71; N, 18.72; S, 7.14%. Found: C, 61.70; H, 4.58; N, 18.90; S, 7.35%.

Ethyl 2-amino-4-(2-(4-chlorophenyl)hydrazono)-5hydrazono-7,7-dimethyl-4,5,6,7-tetra-hydrobenzo[*b*] thiophene-3-carboxylate (8g)

Orange crystals (ethanol), yield 77% (3.22 g), m.p. 236–239 °C; (IR (KBr) ν max 3458–3341, 3055, 2987, 1650, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.29$ (s, 1H, D₂O exchangeable, NH), 7.48–7.24 (m, 4H, C₆H₄), 4.49, 5.15 (2s, 4H, D₂O exchangeable, 2NH₂), 4.21 (q, 2H, J = 7.39 Hz, OCH₂CH₃), 2.70 (s, 2H, CH₂), 1.12 (t, 3H, J = 7.39 Hz, OCH₂CH₃), 1.07, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.3$, 176.1 (C-4, C-5), 165.2 (ester CO), 141.9, 141.2, 136.3, 134.8, 128.9, 125.8, 123.5, 120.3 (C₆H₅, C₆H₄, C-2, C-3, C-3a, C-7a), 52.3 (OCH₂CH₃); 50.2 (C-4), 38.0 (C-7), 24.3 (2CH₃), 19.0 (OCH₂CH₃); EIMS: *m/z* 419 [M]⁺ (42%); Analysis Calcd for C₁₉H₂₂ClN₅O₂S (419.93): C, 54.34; H, 5.28; N, 16.68; S, 7.64%. Found: C, 54.62; H, 5.39; N, 16.88; S, 7.80%.

Ethyl 2-amino-4-(2-(4-chlorophenyl)hydrazono)-7,7dimethyl-5-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo [*b*]thiophene-3-carboxylate (8h)

Reddish brown crystals (ethanol), yield 65% (3.22 g), m.p. 168–170 °C; (IR (KBr) νmax 3473–3326, 3055, 2980, 1650, 1557; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.29$ (s, 1H, D₂O exchangeable, NH), 7.49–7.23 (m, 10H, 2C₆H₅), 4.48 (s, 2H, D₂O exchangeable, NH₂), 4.23 (q, 2H, J = 5.80 Hz, O<u>CH₂CH₃</u>), 2.73 (s, 2H, CH₂), 1.12 (t, 3H, J = 5.80 Hz, OCH₂<u>CH₃</u>), 1.09, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.5$, 176.7 (C-4, C-5), 165.3 (ester CO), 143.4, 142.0, 138.8, 137.3, 134.1, 126.8, 124.1, 123.0, 122.9, 122.6, 121.4, 120.3 (C₆H₅, C₆H₄, C-2, C-3, C-3a, C-7a), 52.6 (O<u>CH₂CH₃</u>), 50.8 (C-4), 38.1 (C-7), 24.0 (2CH₃), 19.2 (OCH₂<u>CH₃</u>); EIMS: *m/z* 496 [M]⁺ (44%); Analysis Calcd for C₂₅H₂₆CIN₅O₂S (496.02): C, 60.53; H, 5.28; N, 14.12; S, 6.46%. Found: C, 60.74; H, 5.41; N, 14.27; S, 6.80%.

2-Amino-5-hydrazono-4-(2-(4-methoxyphenyl)hydrazono)-7,7-dimethyl-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3carbonitrile (8i)

Yellow crystals (ethanol), yield 70% (2.57 g), m.p. 166–168 °C; (IR (KBr) ν max 3493–3331, 3054, 2982, 2220, 1650, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.32 (s, 1H, D₂O exchangeable, NH), 7.45–7.25 (m, 4H, C₆H₄), 4.43, 5.02 (2 s, 4H, D₂O exchangeable, 2NH₂), 3.66 (s, 3H, OCH₃), 2.79 (s, 2H, CH₂), 1.06, 1.01 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.3, 176.1 (C-4, C-5), 143.6, 141.1, 138.5, 136.8, 134.3, 128.8, 123.7, 120.2 (C₆H₄, C-2, C-3, C-3a, C-7a), 117.3 (CN), 50.8 (C-4), 38.2 (C-7), 24.3 (2CH₃); EIMS: *m*/*z* 368 [M]⁺ (31%); Analysis Calcd for C₁₈H₂₀N₆OS (368.46): C, 58.68; H, 5.47; N, 22.81; S, 8.70%. Found: C, 58.72; H, 5.29; N, 22.69; S, 8.83%.

2-Amino-4-(2-(4-methoxyphenyl)hydrazono)-7,7-dimethyl-5-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo[*b*] thiophene-3-carbonitrile (8k)

Red crystals (ethanol), yield 64% (2.84 g), m.p. 244–247 ° C; (IR (KBr) ν max 3482–3340, 3054, 2980, 2220, 1653, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.39$, 8.25 (2s, 2H, D₂O exchangeable, 2NH), 7.49–7.20 (m, 9H, C₆H₅, C₆H₄), 4.44 (s, 2H, D₂O exchangeable, NH₂), 3.72 (s, 3H, OCH₃), 2.73 (s, 2H, CH₂), 1.08, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.8$, 176.2 (C-4, C-5), 142.8, 140.6, 136.2, 133.5, 132.6, 128.3, 126.4, 125.2, 124.5, 123.2, 122.6, 120.3 (C₆H₅, C₆H₄, C-2, C-3, C-3a, C-7a) 116.9 (CN), 52.4 (OCH₃), 50.2 (C-4), 38.3 (C-7), 24.5 (2CH₃); EIMS: *m/z* 444 [M]⁺ (28%); Analysis Calcd for

 $C_{24}H_{24}N_6OS \ (444.55): \ C, \ 64.84; \ H, \ 5.44; \ N, \ 18.90; \ S, \\ 7.21\%. \ Found: \ C, \ 64.62; \ H, \ 5.60; \ N, \ 18.83; \ S, \ 7.29\%.$

Ethyl 2-amino-5-hydrazono-4-(2-(4-methoxyphenyl) hydrazono)-7,7-dimethyl-4,5,6,7-tetrahydrobenzo[*b*] thiophene-3-carboxylate (8l)

Orange crystals (ethanol), yield 78% (3.23 g), m.p. 190–194 °C; (IR (KBr) ν max 3492–3348, 3055, 2987, 1688, 1560; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.27$ (s, 1H, D₂O exchangeable, NH), 7.46–7.23 (m, 4H, C₆H₄), 4.45, 5.18 (2s, 4H, D₂O exchangeable, 2NH₂), 4.22 (q, 2H, J = 5.95 Hz, O<u>CH₂CH₃</u>), 3.76 (s, 3H, OCH₃), 2.68 (s, 2H, CH₂), 1.13 (t, 3H, J = 5.95 Hz, OCH₂<u>CH₃</u>), 1.09, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$, 176.3 (C-4, C-5), 164.8 (ester CO), 142.8, 141.8, 136.6, 134.2, 128.7, 125.6, 124.2, 120.6 (C₆H₅, C-2, C-3, C-3a, C-7a), 52.1 (O<u>CH₂CH₃</u>), 52.6 (OCH₃), 50.0 (C-4), 38.3 (C-7), 24.3 (2CH₃), 19.3 (OCH₂<u>CH₃</u>); EIMS: *m*/*z* 415 [M]⁺ (28%); Analysis Calcd for C₂₀H₂₅N₅O₃S (415.51): C, 57.81; H, 6.06; N, 16.85; S, 7.72%. Found: C, 57.68; H, 5.82; N, 16.93; S, 7.83%.

Ethyl 2-amino-4-(2-(4-methoxyphenyl)hydrazono)-7,7dimethyl-5-(2-phenylhydrazono)-4,5,6,7-tetrahydrobenzo [*b*]thiophene-3-carboxylate (8m)

Orange crystals (ethanol), yield 78% (3.82 g), m.p. 203-206 °C; (IR (KBr) vmax 3483-3342, 3055, 2980, 1689, 1650, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta =$ 8.32, 8.26 (2s, 2H, D₂O exchangeable, 2NH), 7.49-7.23 (m, 9 H, C₆H₅, C₆H₄), 4.52 (s, 2H, D₂O exchangeable, NH₂), 4.20 (q, 2H, J = 6.22 Hz, OCH₂CH₃), 3.70 (s, 3H, OCH₃), 2.75 (s, 2H, CH₂), 1.13 (t, 3H, J = 6.22 Hz, OCH₂CH₃), 1.07, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.3, 176.1 (C-4, C-5), 165.2 (ester CO), 143.2, 141.8,$ 138.3, 136.1, 134.1, 126.84, 125.8, 123.2, 122.3, 121.9, 121.2, 120.6 (C₆H₅, C₆H₄, C-2, C-3, C-3a, C-7a), 116.9 (CN), 53.6 (OCH₃), 52.3 (OCH₂CH₃), 50.8 (C-4), 38.3 (C-7), 24.1 (2CH₃), 18.5 (OCH₂CH₃); EIMS: m/z 491 [M]⁺ (24%); Analysis Calcd for C₂₆H₂₉N₅O₃S (491.61): C, 63.52; H, 5.95; N, 14.25; S, 6.52%. Found: C, 63.80; H, 5.72; N, 14.39; S, 6.76%.

General procedure for the synthesis benzo[4,5]thieno[2,3-*d*] pyrimidine derivatives 10a–f

To a solution of any of compounds 5a (3.24 g, 0.01 mol), 5b (3.71 g, 0.01 mol), 5c (3.58 g, 0.01 mol), 5d (4.05 g, 0.01 mol), 5e (3.54 g, 0.01 mol), or 5f (4.01 g, 0.01 mol) in 1,4-dioxan (40 mL) containing triethylamine (0.50 mL) phenylisothiocyanate was added. The reaction mixture, in each case, was heated under reflux for 6 h then poured onto ice/water containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

4-Amino-8,8-dimethyl-3-phenyl-5-(2-phenylhydrazono)-2thioxo-2,3,7,8-tetrahydro-benzo[4,5]thieno[2,3-*d*]pyrimidin-6(5*H*)-one (10a)

Orange crystals (ethanol), yield 83% (3.80 g), m.p. 180–184 °C; (IR (KBr) ν max 3468–3315, 3056, 2980, 1653, 1552, 1205; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.36 (s, 1H, D₂O exchangeable, NH), 7.42–7.29 (m, 10H, 2C₆H₅), 4.78 (s, 2H, D₂O exchangeable, NH₂), 2.79 (s, 2H, CH₂), 1.08, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 180.1 (C-2), 179.3, 176.1, 165.3 (C-5, C-9a, C-6), 142.8, 141.3, 139.1, 137.1, 134.8, 126.3, 125.2, 124.8, 122.6, 121.8, 121.6, 120.2 (2C₆H₅, C-4, C-4a, C-4b, C-8a), 50.6 (C-7), 38.7 (C-8), 24.3 (2CH₃); EIMS: *m/z* 459 [M]⁺ (18%); Analysis Calcd for C₂₄H₂₉N₅OS₂ (459.59): C, 62.72; H, 4.61; N, 15.24; S, 13.95%. Found: C, 62.59; H, 4.85; N, 15.41; S, 14.22%.

4-Hydroxy-8,8-dimethyl-3-phenyl-5-(2-phenylhydrazono)-2thioxo-2,3,7,8-tetrahydro-benzo[4,5]thieno[2,3-*d*]pyrimidin-6(5*H*)-one (10b)

Yellow crystals (acetic acid), yield 79% (3.63 g), m.p. 211–213 °C; (IR (KBr) ν max 3459–3338, 3054, 2980, 1652, 1550, 1207; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta =$ 10.28 (s, 1H, D₂O exchageable, OH), 8.37 (s, 1H, D₂O exchangeable, NH), 7.40–7.26 (m, 10H, 2C₆H₅), 2.74 (s, 2H, CH₂), 1.06, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta =$ 180.4 (C-2), 179.6, 176.5, 165.7 (C-5, C-9a, C-6), 143.2, 142.6, 138.7, 137.5, 134.1, 128.6, 125.1, 124.5, 123.3, 120.8, 119.8, 119.4 (2C₆H₅, C-4, C-4a, C-4b, C-8a), 50.8 (C-7), 38.3 (C-8), 24.2 (2CH₃); EIMS: *m/z* 460 [M]⁺ (38%); Analysis Calcd for C₂₄H₂₀N₄O₂S₂ (460.57): C, 62.59; H, 4.38; N, 12.16; S, 13.92%. Found: C, 62.42; H, 4.57; N, 12.49; S, 14.16%.

4-Amino-5-(2-(4-chlorophenyl)hydrazono)-8,8-dimethyl-3phenyl-2-thioxo-2,3,7,8-tetrahydrobenzo[4,5]thieno[2,3-*d*] pyrimidin-6(5*H*)-one (10c)

Yellow crystals (acetic acid), yield 68% (3.35 g), m.p. 177–179 °C; (IR (KBr) ν max 3484–3358, 3054, 2980, 1650, 1555, 1205; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.39 (s, 1H, D₂O exchangeable, NH), 7.52–7.23 (m, 9H, C₆H₅, C₆H₄), 4.79 (s, 2H, D₂O exchangeable, NH₂), 2.72 (s, 2H, CH₂), 1.07, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 180.6 (C-2), 179.9, 176.2, 165.4 (C-5, C-9a, C-6), 142.9, 141.4, 139.8, 138.3, 135.6, 130.8, 127.5, 125.2, 123.6, 121.8, 120.5, 120.0 (2C₆H₅, C-4, C-4a, C-4b, C-8a), 50.5 (C-7), 38.3 (C-8), 24.6 (2CH₃); EIMS: *m/z* 494

$$\label{eq:masses} \begin{split} [M]^+ & (42\%); \ Analysis \ Calcd \ for \ C_{24}H_{20}ClN_5OS_2 \ (494.03): \\ C, 58.35; \ H, \ 4.08; \ N, \ 14.18; \ S, \ 12.98\%. \ Found: \ C, \ 58.59; \ H, \\ 4.29; \ N, \ 13.87; \ S, \ 13.14\%. \end{split}$$

5-(2-(4-Chlorophenyl)hydrazono)-4-hydroxy-8,8-dimethyl-3phenyl-2-thioxo-2,3,7,8-tetrahydrobenzo[4,5]thieno[2,3-*d*] pyrimidin-6(5*H*)-one (10d)

Pale yellow crystals (1,4-dioxan), yield 80% (3.95 g), m.p. 215–218 °C; (IR (KBr) ν max 3463–3342, 3056, 2983, 1654, 1550, 1206; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta =$ 10.22 (s, 1H, D₂O exchangeable, OH), 8.35 (s, 1H, D₂O exchangeable, OH), 8.35 (s, 1H, D₂O exchangeable, NH), 7.49–7.21 (m, 9H, C₆H₅, C₆H₄), 2.73 (s, 2H, CH₂), 1.08, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta =$ 180.3 (C-2), 179.5, 176.8, 165.8 (C-5, C-9a, C-6), 142.7, 142.1, 138.4, 136.8, 135.9, 132.5, 127.8, 126.8, 123.3, 121.5, 120.2, 119.3 (2C₆H₅, C-4, C-4a, C-4b, C-8a), 50.8 (C-7), 38.1 (C-8), 24.3 (2CH₃); EIMS: *m/z* 495 [M]⁺ (28%); Analysis Calcd for C₂₄H₁₉ClN₄O₂S₂ (495.02): C, 58.23; H, 3.87; N, 11.32; S, 12.96%. Found: C, 58.41; H, 3.69; N, 11.50; S, 13.25%.

4-Amino-5-(2-(4-methoxyphenyl)hydrazono)-8,8-dimethyl-3-phenyl-2-thioxo-2,3,7,8-tetrahydrobenzo[4,5]thieno[2,3*d*]pyrimidin-6(5*H*)-one (10e)

Yellow crystals (ethanol), yield 80% (3.91 g), m.p. 155–157 °C; (IR (KBr) ν max 3491–3339, 3054, 2985, 1688, 1656, 1551, 1203; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.36$ (s, 1H, D₂O exchangeable, NH), 7.43–7.27 (m, 9 H, C₆H₅, C₆H₄), 4.76 (s, 2H, D₂O exchangeable, NH₂), 3.72 (s, 3H, OCH₃), 2.72 (s, 2H, CH₂), 1.09, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 180.3$ (C-2), 179.5, 176.5, 165.8 (C-5, C-9a, C-6), 142.8, 142.6, 139.2, 137.6, 136.4, 132.3, 127.3, 125.7, 123.2, 121.6, 120.3, 119.6 (2C₆H₅, C-4, C-4a, C-4b, C-8a), 52.6 (OCH₃), 50.2 (C-7), 38.1 (C-8), 24.7 (2CH₃); EIMS: *m/z* 489 [M]⁺ (32%); Analysis Calcd for C₂₅H₂₃N₅O₂S₂ (489.61): C, 61.33; H, 4.73; N, 14.30; S, 13.10%. Found: C, 61.26; H, 4.53; N, 14.25; S, 13.28%.

4-Hydroxy-5-(2-(4-methoxyphenyl)hydrazono)-8,8dimethyl-3-phenyl-2-thioxo-2,3,7,8-tetrahydrobenzo[4,5] thieno[2,3-*d*]pyrimidin-6(5*H*)-one (10f)

Pale yellow crystals (1,4-dioxan), yield 69% (3.38 g), m.p. 150–153 °C; (IR (KBr) ν max 3480–3319, 3054, 2981, 1652, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.29$ (s, 1H, D₂O exchangeable, OH), 8.33 (s, 1H, D₂O exchangeable, NH), 7.46–7.28 (m, 9H, C₆H₅, C₆H₄), 3.77 (s, 3H, OCH₃), 2.71 (s, 2H, CH₂), 1.06, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 180.1$ (C-2), 179.9, 176.5, 165.4 (C-5, C-9a, C-6), 142.8, 142.3, 138.2, 136.5, 135.3,

132.2, 128.9, 125.6, 124.8, 122.8, 120.9, 120.3 ($2C_6H_5$, C-4, C-4a, C-4b, C-8a), 52.6 (OCH₃), 50.3 (C-7), 38.3 (C-8), 24.1 (2CH₃); EIMS: *m/z* 490 [M]⁺ (18%); Analysis Calcd for $C_{25}H_{22}N_4O_3S_2$ (490.60): C, 61.20; H, 4.52; N, 11.42; S, 13.07%. Found: C, 61.38; H, 4.71; N, 11.62; S, 13.19%.

General procedure for the synthesis of the triazolo [4",5":5',6']benzo [1',2':4,5]thieno[2,3-d]pyrimidine derivatives 12a-f

To a solution of any of 10a (4.59 g, 0.01 mol), 10b (4.60 g, 0.01 mol), 10c (4.94 g, 0.01 mol), 10d (4.54 g, 0.01 mol), 10e (4.89 g, 0.01 mol), or 10f (4.90 g, 0.01 mol) in 1,dioxan (50 mL) containing sodium acetate (2.0 g) hydroxylamine hydrochloride (1.40 g, 0.02 mol) was added. The reaction mixture, in each case, was heated under reflux for 3 h then poured onto ice/water and the formed solid product was collected by filtration.

10-Amino-5,5-dimethyl-2,9-diphenyl-4,5-dihydro-2*H*-[1,2,3] triazolo[4″,5″:5′,6′]benzo[1′,2′:4,5]thieno[2,3-*d*]pyrimidin-8 (9 *H*)-one oxime (12a)

Pale yellow crystals (1,4-dioxan), yield 55% (2.50 g), m.p. 173–176 °C; (IR (KBr) ν max 3570–3329, 3057, 2981, 1656, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.42$ (s, 1H, D₂O exchangeable, OH), 7.46–7.28 (m, 10 H, 2C₆H₅), 4.57 (s, 2H, D₂O exchageable, NH₂), 2.78 (s, 2H, CH₂), 1.09, 1.02 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 176.5$, 175.2, 173.6, 170.2 (C-8, C-6a, C-3a, C-10c), 145.2, 144.6, 141.7, 138.2, 135.1, 130.8, 127.3, 125.2, 124.5, 123.5, 122.6, 120.4 (2C₆H₅, C-10, C-10a, C-5a, C-10b), 50.6 (C-4), 38.6 (C-7), 24.3 (2CH₃); EIMS: *m/z* 455 [M]⁺ (20%); Analysis Calcd for C₂₄H₂₁N₇OS (455.53): C, 63.28; H, 4.65; N, 21.52; S, 7.04%. Found: C, 63.52; H, 4.82; N, 21.73; S, 7.27%.

10-Hydroxy-5,5-dimethyl-2,9-diphenyl-4,5-dihydro-2*H*-[1,2,3]triazolo[4",5":5',6']-benzo[1',2':4,5]thieno[2,3-*d*] pyrimidin-8(9 *H*)-one oxime (12b)

Pale yellow crystals (1,4-dioxan), yield 55% (2.50 g), m.p. 203–206 °C; (IR (KBr) ν max 3587–3338, 3054, 2986, 1652, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 10.28, 10.47 (2 s, 2H, D₂O exchangeable, 2OH), 7.48–7.25 (m, 10 H, 2C₆H₅), 2.73 (s, 2H, CH₂), 1.08, 1.04 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 176.8, 175.6, 173.2, 170.8 (C-8, C-6a, C-3a, C-10c), 144.8, 143.3, 140.9, 137.8, 135.1, 132.5, 127.8, 125.5, 123.2, 122.8, 122.3, 120.8 (2C₆H₅, C-10, C-10a, C-5a, C-10b), 50.3 (C-4), 38.2 (C-7), 24.1 (2CH₃); EIMS: *m/z* 456 [M]⁺ (28%); Analysis Calcd for C₂₄H₂₀N₆O₂S (456.52): C, 63.14; H, 4.42; N, 18.41; S, 7.02%. Found: C, 63.35; H, 4.36; N, 18.60; S, 7.29%.

10-Amino-2-(4-chlorophenyl)-5,5-dimethyl-9-phenyl-4,5dihydro-2*H*-[1,2,3]triazolo-[4″,5″:5′,6′]benzo[1′,2′:4,5]thieno [2,3-*d*]pyrimidin-8(9*H*)-one oxime (12c)

Yellow crystals (1,4-dioxan), yield 82% (4.40 g), m.p. 233–237 °C; (IR (KBr) ν max 3593–3352, 3057, 2986, 1653, 1547; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.45$ (s, 1H, D₂O exchangeable, OH), 7.53–7.25 (m, 9 H, C₆H₅, C₆H₄), 4.54 (s, 2H, D₂O exchageable, NH₂), 2.76 (s, 2H, CH₂), 1.07, 1.03 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 176.8$, 175.5, 173.2, 170.5 (C-8, C-6a, C-3a, C-10c), 146.3, 143.3, 140.9, 138.6, 133.5, 130.5, 127.0, 125.8, 124.1, 123.7, 123.2, 120.8 (C₆H₅, C₆H₄, C-10, C-10a, C-5a, C-10b), 50.8 (C-4), 38.9 (C-7), 24.2 (2CH₃); EIMS: *m/z* 489 [M]⁺ (35%); Analysis Calcd for C₂₄H₂₀ClN₇OS (489.98): C, 58.83; H, 4.11; N, 20.01; S, 6.54%. Found: C, 58.93; H, 4.29; N, 20.26; S, 6.80%.

2-(4-Chlorophenyl)-10-hydroxy-5,5-dimethyl-9-phenyl-4,5dihydro-2*H*-[1,2,3]triazolo-[4″,5″:5′,6′]benzo[1′,2′:4,5]thieno [2,3-*d*]pyrimidin-8(9*H*)-one oxime (12d)

Orange crystals (1,4-dioxan), yield 76% (3.72 g), m.p. 155–158 °C; (IR (KBr) ν max 3565–3314, 3055, 2983, 1650, 1555; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.25$, 10.49 (2 s, 2H, D₂O exchangeable, 2OH), 7.53–7.25 (m, 9 H, C₆H₅, C₆H₄), 2.76 (s, 2H, CH₂), 1.07, 1.02 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 176.7$, 174.9, 173.6, 170.3 (C-8, C-6a, C-3a, C-10c), 144.5, 142.7, 140.3, 137.5, 134.8, 132.1, 128.2, 125.9, 124.2, 123.3, 121.8, 120.2 (2C₆H₅, C-10, C-10a, C-5a, C-10b), 50.6 (C-4), 38.5 (C-7), 24.4 (2CH₃); EIMS: *m*/*z* 490 [M]⁺ (17%); Analysis Calcd for C₂₄H₁₉ClN₆O₂S (490.96): C, 58.71; H, 3.90; N, 17.12; S, 6.53%. Found: C, 58.48; H, 4.15; N, 17.37; S, 6.72%.

10-Amino-2-(4-methoxyphenyl)-5,5-dimethyl-9-phenyl-4,5dihydro-2*H*-[1,2,3]triazolo-[4″,5″:5′,6′]benzo[1′,2′:4,5]thieno [2,3-*d*]pyrimidin-8(9*H*)-one oxime (12e)

Pale brown crystals (1,4-dioxan), yield 80% (3.88 g), m.p. 266–269 °C; (IR (KBr) ν max 3574–3341, 3053, 2982, 1650, 1552; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.47$ (s, 1H, D₂O exchangeable, OH), 7.56–7.22 (m, 9 H, C₆H₅, C₆H₄), 4.57 (s, 2H, D₂O exchageable, NH₂), 3.72 (s, 3 H, OCH₃), 2.73 (s, 2H, CH₂), 1.07, 1.05 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 176.3$, 173.4, 172.8, 170.6 (C-8, C-6a, C-3a, C-10c), 145.8, 142.7, 141.3, 138.3, 133.2, 130.9, 126.7, 125.2, 124.8, 123.3, 122.6, 121.4 (C₆H₅, C₆H₅, C-10, C-10a, C-5a, C-10b), 52.8 (OCH₃), 50.4 (C-4), 38.3 (C-7), 24.5 (2CH₃); EIMS: *m*/z 485 [M]⁺ (42%); Analysis Calcd for C₂₅H₂₃N₇O₂S (485.56): C, 61.84; H,

4.77; N, 20.19; S, 6.60%. Found: C, 62.08; H, 4.85; N, 20.38; S, 6.84%.

10-Hydroxy-2-(4-methoxyphenyl)-5,5-dimethyl-9-phenyl-4,5-dihydro-2*H*-[1,2,3]triazolo-[4",5":5',6']benzo[1',2':4,5] thieno[2,3-*d*]pyrimidin-8(9 *H*)-one oxime (12f)

Orange crystals (1,4-dioxan), yield 69% (3.35 g), m.p. 211–214 °C; (IR (KBr) ν max 3595–3334, 3055, 2983, 1652, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.28$, 10.43 (2 s, 2H, D₂O exchangeable, 2OH), 7.56–7.22 (m, 9 H, C₆H₅, C₆H₄), 2.73 (s, 2H, CH₂), 1.08, 1.04 (2 s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 176.8$, 174.3, 173.4, 171.6 (C-8, C-6a, C-3a, C-10c), 143.9, 141.7, 140.6, 137.3, 134.2, 133.7, 128.0, 125.6, 124.8, 122.2, 121.5, 120.4 (C₆H₅, C₆H₄, C-10, C-10a, C-5a, C-10b), 52.8 (OCH₃), 50.9 (C-4), 38.3 (C-7), 24.2 (2CH₃); EIMS: m/z 486 [M]⁺ (24%); Analysis Calcd for C₂₅H₂₂N₆O₃S (486.55): C, 61.71; H, 4.56; N, 17.27; S, 6.59%. Found: C, 61.93; H, 4.80; N, 17.41; S, 6.83%.

General procedure for the synthesis of the thieno[2,3-g] chromene derivatives 14a-m

To a solution of any of compounds **5a** (3.24 g, 0.01 mol), **5b** (3.71 g, 0.01 mol), **5c** (3.58 g, 0.01 mol), **5d** (4.05 g, 0.01 mol), **5e** (3.54 g, 0.01 mol), or **5f** (4.01 g, 0.01 mol) in 1,4-dioxan (40 mL) containing triethylamine (0.50 mL) either of α -cyanocinnamate (1.54 g, 0.01 mol) or ethyl α -cyanocinnamate (2.01 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 6 h then poured onto ice/water containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

2,6-Diamino-9,9-dimethyl-8-phenyl-4-(2-phenylhydrazono)-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7-dicarbonitrile (14a)

Yellow crystals (1,4-dioxan), yield 67% (3.20 g), m.p. 120–123 °C; IR (KBr) ν max 3468–3339, 3054, 2985, 2223, 2220, 1654, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.39 (s, 1H, D₂O exchangeable, NH), 6.13 (s, 1H, H-8), 7.41–7.26 (m, 10H, 2C₆H₅), 4.59, 5.39 (2s, 4H, D₂O exchangeable, 2NH₂), 1.11, 1.05 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.3 (C-4), 144.2, 143.1, 138.6, 137.8, 134.8, 132.1, 128.6, 125.8, 124.7, 123.2, 122.4, 122.9, 121.6, 120.4, 120.3, 119.6 (2C₆H₅, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 38.6 (C-9), 26.9 (C-8), 117.8, 166.7 (2CN), 24.4 (2CH₃); EIMS: *m*/z 478 [M]⁺ (48%); Analysis Calcd for C₂₇H₂₂N₆OS (478.57): C, 67.76; H, 4.63; N, 17.56; S, 6.70%. Found: C, 67.84; H, 4.75; N, 17.80; S, 6.93%.

2-Amino-6-hydroxy-9,9-dimethyl-8-phenyl-4-(2phenylhydrazono)-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7-dicarbonitrile (14b)

Yellow crystals (1,4-dioxan), yield 78% (3.73 g), m.p. 187–190 °C; IR (KBr) ν max 3583–3369, 3056, 2985, 2224, 2220, 1651, 1557; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 10.29 (s, 1H, D₂O exchangeable, OH), 8.37 (s, 1H, D₂O exchangeable, NH), 6.11 (s, 1H, H-8), 7.44–7.23 (m, 10H, 2C₆H₅), 4.68 (s, 2H, D₂O exchangeable, NH₂), 1.14, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.6 (C-4), 144.6, 142.9, 138.3, 137.5, 135.6, 132.4, 128.8, 127.6, 124.2, 123.6, 122.8, 122.1, 121.6, 121.3, 120.8, 120.4 (2C₆H₅, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.5, 116.9 (2CN), 38.9 (C-9), 26.9 (C-8), 24.6 (2CH₃); EIMS: m/z 479 [M]⁺ (35%); Analysis Calcd for C₂₇H₂₁N₅O₂S (479.55): C, 67.62; H, 4.41; N, 14.60; S, 6.69%. Found: C, 67.74; H, 4.63; N, 14.79; S, 6.82%.

Ethyl 2,6-diamino-7-cyano-9,9-dimethyl-8-phenyl-4-(2-phenylhydrazono)-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3-carboxylate (14c)

Pale brown crystals (1,4-dioxan), yield 72% (3.78 g), m.p. 233–236 °C; IR (KBr) ν max 3469–3369, 3050, 2982, 2220, 1653, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.35$ (s, 1H, D₂O exchangeable, NH), 6.13 (s, 1H, H-8), 7.41–7.26 (m, 10H, 2C₆H₅), 4.65, 5.28 (2s, 4H, D₂O exchangeable, 2NH₂), 4.22 (q, 2H, J = 6.93 Hz, OCH₂CH₃), 1.15 (t, 3H, J = 6.93 Hz, OCH₂CH₃), 1.13, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$ (C-4), 144.6, 142.9, 138.3, 137.5, 135.6, 132.4, 128.8, 126.4, 124.2, 122.8, 122.3, 122.1, 121.6, 121.3, 120.8, 120.4 (2C₆H₅, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.0 (CN), 52.8 (OCH₂CH₃); EIMS: *m*/z 525 [M]⁺ (48%); Analysis Calcd for C₂₉H₂₇N₅O₃S (525.62): C, 66.27; H, 5.18; N, 13.32; S, 6.10%. Found: C, 66.48; H, 5.25; N, 13.57; S, 6.26%.

Ethyl 2-amino-7-cyano-6-hydroxy-9,9-dimethyl-8-phenyl-4-(2-phenylhydrazono)-8,9-dihydro-4*H*-thieno[2,3-*g*] chromene-3-carboxylate (14d)

Pale brown crystals (1,4-dioxan), yield 78% (4.10 g), m.p. 195–197 °C; IR (KBr) ν max 3573–3324, 3050, 2982, 2221, 1650, 1554; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.42$ (s, 1H, D₂O exchangeable, OH), 8.32 (s, 1H, D₂O exchangeable, NH), 6.16 (s, 1H, H-8), 7.44–7.25 (m, 10H, 2C₆H₅), 4.68 (s, 2H, D₂O exchangeable, NH₂), 4.21 (q, 2H, J = 5.79 Hz, OCH₂CH₃), 1.15 (t, 3H, J = 5.79 Hz, OCH₂CH₃), 1.15 (t, 3H, J = 5.79 Hz, OCH₂CH₃), 1.15, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.2$ (C-4), 143.8, 142.2, 138.6, 136.3, 135.2, 133.9,

128.3, 126.7, 125.2, 123.3, 122.4, 121.8, 121.3, 121.0, 120.4, 119.6 (2C₆H₅, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 116.6 (CN), 52.9 (O<u>CH₂CH₃</u>), 38.7 (C-9), 26.4 (C-8), 24.5 (2CH₃), 19.6 (OCH₂<u>CH₃</u>); EIMS: m/z 526 [M]⁺ (22%); Analysis Calcd for C₂₉H₂₆N₄O₄S (526.61): C, 66.14; H, 4.98; N, 10.64; S, 6.09%. Found: C, 66.26; H, 5.18; N, 10.19; S, 6.18%.

2,6-Diamino-4-(2-(4-chlorophenyl)hydrazono)-9,9-dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7dicarbonitrile (14e)

Pale orange crystals (1,4-dioxan), yield 65% (3.34 g), m.p. 186–189 °C; (IR (KBr) ν max 3439–3314, 3057, 2982, 2222, 2220, 1654, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.36$ (s, 1H, D₂O exchangeable, NH), 6.12 (s, 1H, H-8), 7.49–7.22 (m, 9H, C₆H₅, C₆H₄), 4.62, 5.35 (2s, 4H, D₂O exchangeable, 2NH₂), 1.10, 1.04 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.6$ (C-4), 143.8, 143.1, 139.2, 135.2, 133.9, 132.0, 128.8, 127.3, 126.8, 125.7, 123.4, 122.1, 122.5, 121.3, 120.1, 119.5 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.4, 116.5 (2CN), 38.7 (C-9), 26.3 (C-8), 24.4 (2CH₃); EIMS: *m*/*z* 513 [M]⁺ (34%); Analysis Calcd for C₂₇H₂₁ClN₆OS (513.01): C, 63.21; H, 4.13; N, 16.38; S, 6.25%. Found: C, 63.47; H, 4.29; N, 16.52; S, 6.41%.

2-Amino-4-(2-(4-chlorophenyl)hydrazono)-6-hydroxy-9,9dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7-dicarbonitrile (14f)

Yellow crystals (1,4-dioxan), yield 80% (4.10 g), m.p. 266–270 °C; (IR (KBr) ν max 3563–3349, 3055, 2983, 2223, 2220, 1654, 1553; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.32$ (s, 1H, D₂O exchangeable, OH), 8.39 (s, 1H, D₂O exchangeable, NH), 6.13 (s, 1H, H-8), 7.48–7.21 (m, 9H, C₆H₅, C₆H₄), 4.63 (s, 2H, D₂O exchangeable, NH₂), 1.12, 1.05 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.8$ (C-4), 143.3, 142.2, 138.6, 136.9, 133.4, 132.8, 129.0, 127.5, 125.6, 123.1, 122.9, 122.3, 121.4, 121.0, 120.6, 120.1 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.1, 116.7 (2CN), 38.9 (C-9), 26.7 (C-8), 24.3 (2CH₃); EIMS: *m/z* 514 [M]⁺ (42%); Analysis Calcd for C₂₇H₂₀ClN₅O₂S (514.00): C, 63.09; H, 3.92; N, 13.63S, 6.24%. Found: C, 62.95; H, 4.19; N, 13.58; S, 6.57%.

Ethyl 2,6-diamino-4-(2-(4-chlorophenyl)hydrazono)-7cyano-9,9-dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3-*g*] chromene-3-carboxylate (14g)

Pale brown crystals (1,4-dioxan), yield 80% (4.48 g), m.p. 189–192 °C; (IR (KBr) vmax 3448–3329, 3050, 2982,

2222, 1650, 1554; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 8.38 (s, 1H, D₂O exchangeable, NH), 6.15 (s, 1H, H-8), 7.49–7.23 (m, 9H, C₆H₅, C₆H₄), 4.63, 5.25 (2s, 4H, D₂O exchangeable, 2NH₂), 4.24 (q, 2H, J = 7.19 Hz, OCH₂CH₃), 1.14 (t, 3H, J = 7.19 Hz, OCH₂CH₃), 1.13, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 179.3 (C-4), 143.3, 142.6, 138.8, 136.1, 135.8, 132.2, 128.8, 126.4, 125.3, 124.3, 123.4, 122.8, 121.1, 121.6, 120.3, 119.4 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.0 (CN), 52.4 (OCH₂CH₃); 8.5 (C-9), 26.3 (C-8), 24.3 (2CH₃), 19.4 (OCH₂CH₃); EIMS: *m*/*z* 560 [M]⁺ (48%); Analysis Calcd for C₂₉H₂₆ClN₅O₃S (560.07): C, 62.19; H, 4.68; N, 12.50; S, 5.73%. Found: C, 62.30; H, 4.72; N, 12.69; S, 5.82%.

Ethyl 2-amino-4-(2-(4-chlorophenyl)hydrazono)-7-cyano-6hydroxy-9,9-dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3*g*]chromene-3-carboxylate (14h)

Brown crystals (1,4-dioxan), yield 58% (3.25 g), m.p. 210-213 °C; (IR (KBr) vmax 3559-3346, 3050, 2980, 2220, 1650, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta =$ 10.44 (s, 1H, D₂O exchangeable, OH), 8.32 (s, 1H, D₂O exchangeable, NH), 6.16 (s, 1H, H-8), 7.44-7.25 (m, 9H, C₆H₅, C₆H₄), 4.69 (s, 2H, D₂O exchangeable, NH₂), 4.26 $(q, 2H, J = 5.79 \text{ Hz}, \text{ OCH}_2\text{CH}_3), 1.13 (t, 3H, J = 5.79 \text{ Hz},$ OCH₂CH₃), 1.17, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO d_{6} , 75 MHz): $\delta = 178.8$ (C-4), 145.2, 142.7, 138.9, 137.4, 135.8, 133.2, 126.8, 125.4, 124.7, 123.1, 123.0, 122.8, 121.6, 121.2, 120.4, 119.9 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 116.8 (CN), 52.4 (OCH₂CH₃), 38.9 (C-9), 26.2 (C-8), 24.5 (2CH₃), 19.5 (OCH₂CH₃); EIMS: m/z 561 [M]⁺ (38%); Analysis Calcd for C₂₉H₂₅ClN₄O₄S (561.05): C, 62.08; H, 4.49; N, 9.99; S, 5.72%. Found: C, 61.93; H, 4.73; N, 10.07; S, 5.95%.

2,6-Diamino-4-(2-(4-methoxyphenyl)hydrazono)-9,9dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7-dicarbonitrile (14i)

Pale orange crystals (1,4-dioxan), yield 83% (4.21 g), m.p. 244–248 °C; (IR (KBr) ν max 3459–3316, 3053, 2982, 2225, 2220, 1652, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 8.39$ (s, 1H, D₂O exchangeable, NH), 6.14 (s, 1H, H-8), 7.46–7.25 (m, 9H, C₆H₅, C₆H₄), 4.64, 5.32 (2s, 4H, D₂O exchangeable, 2NH₂), 3.71 (s, 3H, OCH₃), 1.08, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.9$ (C-4), 145.2, 143.6, 139.6, 135.4, 134.3, 132.6, 127.3, 126.3, 125.9, 124.7, 123.6, 122.9, 122.2, 121.8, 120.7, 120.3 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.2, 116.9 (2CN), 52.6 (OCH₃), 38.5 (C-9), 26.5 (C-8), 24.6 (2CH₃); EIMS: *m/z* 508 [M]⁺ (46%); Analysis Calcd for C₂₈H₂₄N₆O₂S (508.59): C, 66.12; H, 4.76; N,

16.52; S, 6.30%. Found: C, 66.03; H, 4.68; N, 16.75; S, 6.52%.

2-Amino-6-hydroxy-4-(2-(4-methoxyphenyl)hydrazono)-9,9dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno[2,3-*g*]chromene-3,7-dicarbonitrile (14k)

Yellow crystals (1,4-dioxan), yield 77% (3.91 g), m.p. 230–234 °C; (IR (KBr) ν max 3579–3318, 3055, 2982, 2224, 2220, 1653, 1556; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta = 10.36$ (s, 1H, D₂O exchangeable, OH), 8.33 (s, 1H, D₂O exchangeable, NH), 6.11 (s, 1H, H-8), 7.52–7.24 (m, 9H, C₆H₅, C₆H₄), 4.60 (s, 2H, D₂O exchangeable, NH₂), 3.69 (s, 3H OCH₃), 1.15, 1.03 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): $\delta = 179.4$ (C-4), 145.1, 143.6, 137.9, 134.8, 133.5, 132.1, 127.5, 126.1, 125.9, 123.4, 122.7, 122.1, 121.7, 120.3, 120.1, 119.7 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 117.3, 116.9 (2CN), 52.6 (OCH₃), 38.6 (C-9), 26.3 (C-8), 24.4 (2CH₃); EIMS: *m*/z 509 [M]⁺ (28%); Analysis Calcd for C₂₈H₂₃N₅O₃S (509.58): C, 66.00; H, 4.55; N, 13.74, S, 6.29%. Found: C, 65.80; H, 4.39; N, 13.83; S, 6.41%.

Ethyl 2,6-diamino-7-cyano-4-(2-(4-methoxyphenyl) hydrazono)-9,9-dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno [2,3-*g*]chromene-3-carboxylate (14l)

Pale brown crystals (1,4-dioxan), yield 77% (4.27 g), m.p. 240-243 °C; (IR (KBr) vmax 3443-3329, 3055, 2982, 2222, 1653, 1550; ¹H-NMR (DMSO-d₆, 200 MHz): $\delta =$ 8.36 (s, 1H, D₂O exchangeable, NH), 6.12 (s, 1H, H-8), 7.47-7.25 (m, 9H, C₆H₅, C₆H₄), 4.68, 5.28 (2s, 4H, D₂O exchangeable, $2NH_2$, 4.21 (q, 2H, J = 7.36 Hz, OCH₂CH₃), 3.70 (s, 3H, OCH₃), 1.12 (t, 3H, J = 7.36 Hz, OCH₂CH₃), 1.09, 1.02 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO d_6 , 75 MHz): $\delta = 179.2$ (C-4), 145.6, 143.2, 138.6, 136.6, 135.2, 133.8, 128.5, 127.3, 126.9, 124.6, 123.2, 122.7, 121.4, 121.2, 120.2, 120.0 (2C₆H₅, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 116.8 (CN), 52.9 (OCH₂CH₃), 52.6 (OCH₃), 38.3 (C-9), 26.4 (C-8), 24.5 (2CH₃), 19.6 (OCH_2CH_3) ; EIMS: m/z 555 $[M]^+$ (28%); Analysis Calcd for C₃₀H₂₉N₅O₄S (555.65): C, 64.85; H, 5.26; N, 12.60; S, 5.77%. Found: C, 64.94; H, 5.07; N, 12.48; S, 5.79%.

Ethyl 2-amino-7-cyano-6-hydroxy-4-(2-(4-methoxyphenyl) hydrazono)-9,9-dimethyl-8-phenyl-8,9-dihydro-4*H*-thieno [2,3-*g*]chromene-3-carboxylate (14m)

Brown crystals (1,4-dioxan), yield 78% (4.33 g), m.p. 188–191 °C; (IR (KBr) ν max 3574–3325, 3050, 2980, 2221, 1653, 1551; ¹H-NMR (DMSO-d₆, 200 MHz): δ = 10.48 (s, 1H, D₂O exchangeable, OH), 8.31 (s, 1H, D₂O exchangeable, NH), 6.19 (s, 1H, H-8), 7.48–7.25 (m, 9H, C₆H₅,

C₆H₄), 4.71 (s, 2H, D₂O exchangeable, NH₂), 4.23 (q, 2H, J = 6.02 Hz, O<u>CH₂CH₃</u>), 3.68 (s, 3H, OCH₃), 1.12 (t, 3H, J = 6.02 Hz, OCH₂<u>CH₃</u>), 1.19, 1.01 (2s, 6H, 2CH₃); ¹³C-NMR (DMSO-d₆, 75 MHz): δ = 178.5 (C-4), 144.8, 143.3, 138.6, 136.1, 135.4, 133.8, 127.4, 126.5, 125.2, 123.6, 123.0, 122.5, 121.8, 121.7, 120.4, 119.4 (C₆H₅, C₆H₄, C-2, C-3, C-6, C-7, C-3a, C-4a, C-8a, C-9a), 116.6 (CN), 52.3 (O<u>CH₂CH₃</u>), 38.6 (C-9), 26.5 (C-8), 24.2 (2CH₃), 19.3 (OCH₂<u>CH₃</u>); EIMS: *m*/*z* 556 [M]⁺ (40%); Analysis Calcd for C₃₀H₂₈N₄O₅S (556.63): C, 64.73; H, 5.07; N, 10.07; S, 5.76%. Found: C, 64.69; H, 4.95; N, 10.26; S, 5.83%.

Conclusion

In conclusion, an efficient and practical synthesis of new series of thiophene derivatives were synthesized and characterized. The c-Met kinase activity and the antiproliferative activities of compounds were evaluated against five c-Met-dependent cancer cell lines (A549, HT-29, MKN-45, U87MG, and SMMC-7721) and one c-Met-independent cancer cell line (H460) the results showed that compounds **3c**, **5c**, **5d**, **6c**, **6d**, **8f**, **8g**, **8h**, **12c**, **12d**, **12f**, and **14f** were the most active compounds. The Pim-1 kinase inhibition activity of some selected compounds showed that compounds **3c**, **6c**, **8g**, **12c**, and **14f** were high potencies toward Pim-1 kinases.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

References

- Abdelhamid AA, Mohamed SK, Maharramov AM, Khlalilov AN, Allahverdiev MA (2014) Facile and efficient synthesis of acridinediones from primary amino alcohols via three-component condensation reactions assisted by microwave irradiation. J Saudi Chem Soc 18:474–478
- Al-Majid AM, Islam MS, Barakat S, Al-Qahtani NJ, Yousef S, Choudhary MI (2017) Tandem Knoevenagel–Michael reactions in aqueous diethylamine medium: a greener and efficient approach toward bis-dimedone derivatives. Arab J Chem 10:185–193
- Amoozadeh A, Tabrizian E, Rahmani S (2015) Nano titania-supported sulfonic acid catalyzed synthesis of α, α' -bis(substituted-benzylidene)cycloalkanones and of their xanthene derivatives under solvent-free conditions. Comptes Ren Chim 18:848–857
- Bacco FD, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer 103:645–661
- Chassaing S, Specklin S, Weibel JM, Pale P (2012) Vinyl triflates derived from 1,3-dicarbonyl compounds and analogs: access and applications to organic synthesis. Tetrahedron 68:7245–7273

- Darvish F, Balalaei S, Chadegani F, Salehi P (2007) Diammonium hydrogen. phosphate as a neutral and efficient catalyst for synthesis of 1,8-dioxo-. octahydroxanthene derivatives in aqueous media. Synth Commun 37:1059–1066
- Deb ML, Bhuyan PJ (2005) Uncatalysed Knoevenagel condensation in aqueous mediumat room temperature. Tetrahedron Lett 46:6453–6456
- Drew MGB (1982) Phenylhydrazone derivatives of dimedone: hydrogen bonding, spectral (¹³C and H nuclear magnetic resonance) and conformational considerations. Crystal and molecular structures of 5,5-dimethylcyclohexane-1, 2,3-trione 2-(4-methylphenylhydrazone) (1) and 5, 5-dimethylcyclohexane-1,2,3-trione 2-(4-nitrophenylhydrazone) (2). J Chem Soc Perkin Trans II:1297–1303
- Dutra LG, Saibert C, Vicentini DS, Sa MM (2014) Diazo transfer reaction to 1,3-dicarbonyl compounds with sulfonyl azides catalyzed by molecular sieves. J Mol Catal A: Chem 386:35–41
- Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Alle S, Kallan NC, Levis M (2012) potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res 36:224–231
- Gurumurthi S, Sundari V, Valliappan R (2009) An efficient and convenient approach to synthesis of tetrahydrobenzo[*b*]pyran derivatives using tetrabutylammonium Bromide as Catalyst. E-J Chem 6(S1):S466–S472
- Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386–396
- Ilangovan A, Malayappasamy S, Muralidharan S, Maruthamuthu S (2011) A highly efficient green synthesis of 1, 8-dioxooctahydroxanthenes. Chem Cent 5:81
- Jiao C, Jian Sm Chao-guo Y (2011) Synthesis of spiro dihydrofurans and 1,8-dioxo-xanthenes via DABCO catalyzed tandem reaction of aldehyde with cyclohexane-1,3-dione and dimedone. Chem Res Chin Univ 27:49–53
- Jin TS, Zhang JS, Wang AQ, Li TS (2006) Ultrasound-assisted synthesis of 1,8-dioxo-octahydroxanthene derivatives catalyzed by p-dodecylbenzenesulfonic acid in aqueous media. Ultrason Sonochem 13:220–224
- Khurana JM, Magoo D (2009) Efficient one-pot syntheses of 2Hindazolo[2,1-b] phthalazine-triones by catalytic H2SO4 in water–ethanol or ionic liquid. Tetrahedron Lett 52:7300–7303
- Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Woude GF (2002) High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60:1113–1117
- Li S, Huang Q, Liu Y, Zhang X, Liu S, He C, Gong P (2013) Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. Eur J Med Chem 64:62–73
- Liu J, Nie M, Wang Y, Hu J, Zhang F, Gao Y, Liu Y, Gong P (2016) Design, synthesis and structure-activity relationships of novel 4phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors. Eur J Med Chem 123:431–446
- Maripi S, Korupolu RB, Madasu SB (2017) Nano nickel-cobalt ferrite catalysed one-pot multi-component synthesis of xanthenediones and acridinediones GSC 7:70–84
- Mohareb RM, Abdo NY, Wardakhan WW (2017) Synthesis and evaluation of pyrazolo[5,1-b]quinazoline-2- carboxylate, and its thiazole derivatives as potential antiproliferative agents and Pim-1 kinase inhibitors. Med Che, Res 26:2520–2537
- Mohareb RM, Al-Omran F, Ibrahim RA, (2018) The uses of cyclohexan-1,4-dione for the synthesis of thiophene derivatives as new anti-proliferative, prostate anticancer, c-Met and tyrosine kinase inhibitors Med Chem Research 27:618–633

- Nadaraj V, Selvi ST, Mohan S (2009) Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[*c*] acridin-8(9*H*)-one derivatives. Eur J Med Chem 44:976–980
- Neimi H, Nazif ZS (2014) A facile one-pot ultrasound assisted synthesis of 1,8-dioxo-octahydroxanthene derivatives catalyzed by Brønsted acidic ionic liquid (BAIL) under green conditions. J Ind Engin Chem 20:1043–1049
- Nikoofar K, Yielzoleh FM (2017) A concise study on dimedone: a versatile molecule in multi-component reactions, an outlook to the green reaction media. J Saudi Chem Soc (in press).
- Rostamizadeh S, Amani AM, Mahdavinia GH, Amiri G, Sepehrian A (2010) Ultrasound promoted rapid and green synthesis of 1,8dioxo-octahydroxanthenes derivatives using nanosized MCM-41-SO₃H as a nanoreactor, nanocatalyst in aqueous media. Ultrason Sonochem 17:306–309
- Silva ML, Teixeira RR, Santos LA, Martins FT, Ramahho TC (2018) Structural analysis of two tetraketones and theoretical investigation of the reactions involved in their preparation. J Mol Struct 1156:700–711
- Takayuki N, Osamu T, Atsumi Y, Tomohiro M, Keiko T, Setsuo F, Shuji S, Makoto A, Hiroshi O (2010) E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 101:210–215
- Tang Q, Wang L, Tu Y, Zhu W, Luo R, Tu Q, Wang P, Wu C, Gong P, Zheng P (2016) Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Bioorg Med Chem Lett 26:1680–1684
- Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D,

Drueckes P, Wartmann M, McCarthy C, Sellers WR, Hofmann FA (2011) Drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71:5255–5264

- Venkatesan K, Pujari SS, Lahoti RJ, Srinivasan KV (2008) An efficient synthesis of 1,8-dioxo-octahydro-xanthene derivatives promoted by a room temperature ionic liquid at ambient conditions under ultrasound irradiation. Ultrason Sonochem 15:548–553
- Venkatesan K, Suresh S, Lahoti RJ, Srinivasa KV (2008) An efficient synthesis of 1,8-dioxo-octahydro-xanthene derivatives promoted by a room temperature ionic liquid at ambient conditions under ultrasound irradiation. Ultrason Sonochem 15:548–553
- Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67:967–975
- Yadav JS, Subba BV, Rao R, Narender R (2009) InBr₃-catalyzed annulations of cyclic 1,3-diketones with aryl propargyl alcohols: a novel synthesis of 2,4-diaryldihydropyrans. Tetrahedron Lett 50:3963–3965
- Zhang Z, Lee JC, Li L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choin YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG (2012) Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer. Nat Genet 44:852–860